

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

July 27, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/465,124

FILING DATE: April 24, 2003

RELATED PCT APPLICATION NUMBER: PCT/US04/12157

REC'D 30 JUL 2004

WIPO

PCT

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS



N. Woodson
N. WOODSON
Certifying Officer

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

~~4-25-3~~ ~~APPROVED FOR USE THROUGH 10/31/2002~~ ~~N/A PROV~~

SUBSTITUTE for Provisional Application for Patent Cover Sheet PTO/SB/16 (10-01)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53 (c).

| | | | |
|---|------------------|--|--|
| DOCKET NUMBER | | 21300PV | |
| INVENTOR(S) | | | |
| Given Name (first and middle [if any]) | | Family Name or Surname | |
| Mark T. Craig W. Zhijian | | Bilodeau Lindsley Zhao | |
| Residence (City and either State or Foreign Country) | | | |
| Sumneytown Pike, Pennsylvania Schwenksville, Pennsylvania Wilmington, Delaware | | | |
| <input type="checkbox"/> Additional inventors are being named on the separately numbered sheets attached hereto | | | |
| TITLE OF THE INVENTION (500 characters max) | | | |
| INHIBITORS OF AKT ACTIVITY | | | |
| CORRESPONDENCE ADDRESS | | | |
| Direct all Correspondence to: Merck & Co., Inc. Patent Department - RY60-30 P.O. Box 2000 Rahway | | | |
| <input checked="" type="checkbox"/> Customer Number | | 000210 | |
| STATE | New Jersey | ZIP CODE | 07065 |
| COUNTRY | | U.S.A. | |
| ENCLOSED APPLICATION PARTS (check all that apply) | | | |
| <input checked="" type="checkbox"/> Specification | Number of Pages | 90 | <input type="checkbox"/> CD(s), Number |
| <input type="checkbox"/> Drawing(s) | Number of Sheets | 0 | <input type="checkbox"/> Other (specify) |
| <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76 | | | |
| METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT (check one) | | | |
| <input type="checkbox"/> A check or money order is enclosed to cover the filing fees | | <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: | |
| 13-2755 | | FILING FEE AMOUNT (\$) | \$160.00 |

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☒ No.

☐ Yes, the name of the U.S. Government agency and the Government contract number are:

Respectfully submitted,

SIGNATURE

Date | 04/24/2003

TYPED or PRINTED NAME Matthew A. Leff

REGISTRATION NO. 50,149
(if appropriate)

TELEPHONE (732) 594-1404

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT April 24, 2003

EXPRESS MAIL NO. EV 162775848US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.

MAILED BY Christina Cuffe **DATE** 4-24-03

In Duplicate

INHIBITORS OF AKT ACTIVITY

BACKGROUND OF THE INVENTION

Apoptosis (programmed cell death) plays essential roles in embryonic development and pathogenesis of various diseases, such as degenerative neuronal diseases, cardiovascular diseases and cancer. Recent work has led to the identification of various pro- and anti-apoptotic gene products that are involved in the regulation or execution of programmed cell death. Expression of anti-apoptotic genes, such as Bcl2 or Bcl-x_L, inhibits apoptotic cell death induced by various stimuli. On the other hand, expression of pro-apoptotic genes, such as Bax or Bad, leads to programmed cell death (Aams et al. *Science*, 281:1322-1326 (1998)). The execution of programmed cell death is mediated by caspase-1 related proteinases, including caspase-3, caspase-7, caspase-8 and caspase-9 etc (Thornberry et al. *Science*, 281:1312-1316 (1998)).

- 1 -

blocked the activation of Akt by upstream kinases. In addition, introduction of constitutively active PI3K or Akt mutants promotes cell survival under conditions in which cells normally undergo apoptotic cell death (Kulik et al. 1997, Dudek et al. 1997).

5 Three members of the Akt subfamily of second-messenger regulated serine/threonine protein kinases have been identified and termed Akt1/PKB α , Akt2/PKB β , and Akt3/PKB γ (hereinafter referred to as "Akt1", "Akt2" and "Akt3"), respectively. The isoforms are homologous, particularly in regions encoding the catalytic domains. Akts are activated by phosphorylation events occurring in response
10 to PI3K signaling. PI3K phosphorylates membrane inositol phospholipids, generating the second messengers phosphatidyl-inositol 3,4,5-trisphosphate and phosphatidylinositol 3,4-bisphosphate, which have been shown to bind to the PH domain of Akt. The current model of Akt activation proposes recruitment of the enzyme to the membrane by 3'-phosphorylated phosphoinositides, where
15 phosphorylation of the regulatory sites of Akt by the upstream kinases occurs (B.A. Hemmings, *Science* 275:628-630 (1997); B.A. Hemmings, *Science* 276:534 (1997); J. Downward, *Science* 279:673-674 (1998)).

 Phosphorylation of Akt1 occurs on two regulatory sites, Thr³⁰⁸ in the catalytic domain activation loop and on Ser⁴⁷³ near the carboxy terminus (D. R. Alessi
20 *et al. EMBO J.* 15:6541-6551 (1996) and R. Meier *et al. J. Biol. Chem.* 272:30491-30497 (1997)). Equivalent regulatory phosphorylation sites occur in Akt2 and Akt3. The upstream kinase, which phosphorylates Akt at the activation loop site has been cloned and termed 3'-phosphoinositide dependent protein kinase 1 (PDK1). PDK1
25 phosphorylates not only Akt, but also p70 ribosomal S6 kinase, p90RSK, serum and glucocorticoid-regulated kinase (SGK), and protein kinase C. The upstream kinase phosphorylating the regulatory site of Akt near the carboxy terminus has not been identified yet, but recent reports imply a role for the integrin-linked kinase (ILK-1), a serine/threonine protein kinase, or autophosphorylation.

 Analysis of Akt levels in human tumors showed that Akt2 is
30 overexpressed in a significant number of ovarian (J. Q. Cheung *et al. Proc. Natl. Acad. Sci. U.S.A.* 89:9267-9271(1992)) and pancreatic cancers (J. Q. Cheung *et al. Proc. Natl. Acad. Sci. U.S.A.* 93:3636-3641 (1996)). Similarly, Akt3 was found to be overexpressed in breast and prostate cancer cell lines (Nakatani *et al. J. Biol. Chem.* 274:21528-21532 (1999)).

The tumor suppressor PTEN, a protein and lipid phosphatase that specifically removes the 3' phosphate of PtdIns(3,4,5)-P₃, is a negative regulator of the PI3K/Akt pathway (Li et al. *Science* 275:1943-1947 (1997), Stambolic et al. *Cell* 95:29-39 (1998), Sun et al. *Proc. Natl. Acad. Sci. U.S.A.* 96:6199-6204 (1999)).

5 Germline mutations of PTEN are responsible for human cancer syndromes such as Cowden disease (Liaw et al. *Nature Genetics* 16:64-67 (1997)). PTEN is deleted in a large percentage of human tumors and tumor cell lines without functional PTEN show elevated levels of activated Akt (Li et al. *supra*, Guldberg et al. *Cancer Research* 57:3660-3663 (1997), Risinger et al. *Cancer Research* 57:4736-4738 (1997)).

10 These observations demonstrate that the PI3K/Akt pathway plays important roles for regulating cell survival or apoptosis in tumorigenesis.

Inhibition of Akt activation and activity can be achieved by inhibiting PI3K with inhibitors such as LY294002 and wortmannin. However, PI3K inhibition has the potential to indiscriminately affect not just all three Akt isozymes but also
15 other PH domain-containing signaling molecules that are dependent on PtdIns(3,4,5)-P₃, such as the Tec family of tyrosine kinases. Furthermore, it has been disclosed that Akt can be activated by growth signals that are independent of PI3K.

Alternatively, Akt activity can be inhibited by blocking the activity of the upstream kinase PDK1. No specific PDK1 inhibitors have been disclosed. Again,
20 inhibition of PDK1 would result in inhibition of multiple protein kinases whose activities depend on PDK1, such as atypical PKC isoforms, SGK, and S6 kinases (Williams et al. *Curr. Biol.* 10:439-448 (2000)).

It is an object of the instant invention to provide novel compounds that are inhibitors of Akt.

25 It is also an object of the present invention to provide pharmaceutical compositions that comprise the novel compounds that are inhibitors of Akt.


It is also an object of the present invention to provide a method for treating cancer that comprises administering such inhibitors of Akt activity.

SUMMARY OF THE INVENTION

The instant invention provides for compounds which comprise heterocyclic triazines that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.

DETAILED DESCRIPTION OF THE INVENTION

The compounds of the instant invention are useful in the inhibition of the activity of the serine/threonine kinase Akt. In a first embodiment of this invention, the inhibitors of Akt activity are illustrated by the Formula A:



wherein:

15 $W=Y$ is selected from $CR^1=N$, $N=CR^1$, $\overset{\text{O}}{\parallel}C-NR^{1'}$ or $R^{1'}N-\overset{\text{O}}{\parallel}C$;

a is 0 or 1;

b is 0 or 1;

m is 0, 1 or 2;

20 p is 0, 1 or 2;

q is 0, 1, 2 or 3;

r is 0 or 1;

s is 0 or 1;

t is 2, 3, 4, 5 or 6;

25

Q is selected from: H, $-NR^6R^7$, aryl and heterocyclyl, said aryl and heterocyclyl which is optionally substituted with one to three R^Z ;

R^1 is independently selected from:

- 5 1) H,
- 2) $(C=O)_aO_bC_1-C_{10}$ alkyl,
- 3) $(C=O)_aO_b$ aryl,
- 4) C_2-C_{10} alkenyl,
- 5) C_2-C_{10} alkynyl,
- 10 6) $(C=O)_aO_b$ heterocyclyl,
- 7) $(C=O)_aO_bC_3-C_8$ cycloalkyl,
- 8) CO_2H ,
- 9) halo,
- 10) CN,
- 15 11) OH,
- 12) $O_bC_1-C_6$ perfluoroalkyl,
- 13) $O_a(C=O)_bNR^6R^7$,
- 14) $NR^c(C=O)NR^6R^7$,
- 15) $S(O)_mR^a$,
- 20 16) $S(O)_2NR^6R^7$,
- 17) $NR^cS(O)_mR^a$,
- 18) oxo,
- 19) CHO,
- 20) NO_2 ,
- 25 21) $NR^c(C=O)O_bR^a$,
- 22) $O(C=O)O_bC_1-C_{10}$ alkyl,
- 23) $O(C=O)O_bC_3-C_8$ cycloalkyl,
- 24) $O(C=O)O_b$ aryl,
- 25) $O(C=O)O_b$ -heterocycle, and
- 30 26) $O_a-P=O(OH)_2$,

said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one or more substituents selected from R^Z ;

$R^{1'}$ is independently selected from:

- 1) H,
- 2) $(C=O)_aO_bC_1-C_{10}$ alkyl,
- 3) $(C=O)_aO_b$ aryl,
- 4) C_2-C_{10} alkenyl,
- 5) C_2-C_{10} alkynyl,
- 6) $(C=O)_aO_b$ heterocyclyl,
- 7) $(C=O)_aO_bC_3-C_8$ cycloalkyl,
- 8) CO_2H ,
- 9) halo,
- 10) CN,
- 11) OH,
- 12) $O_bC_1-C_6$ perfluoroalkyl,
- 13) $O_a(C=O)_bNR^6R^7$,
- 14) $S(O)_mR^a$,
- 15) $S(O)_2NR^6R^7$,
- 16) oxo,
- 17) CHO,
- 18) $O(C=O)O_bC_1-C_{10}$ alkyl,
- 19) $O(C=O)O_bC_3-C_8$ cycloalkyl,
- 20) $O(C=O)O_b$ aryl,
- 21) $O(C=O)O_b$ -heterocycle, and
- 22) $O_a-P=O(OH)_2$,

said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one or more substituents selected from R^Z ;

25

R^2 is independently selected from:

- 1) $(C=O)_aO_bC_1-C_{10}$ alkyl,
- 2) $(C=O)_aO_b$ aryl,
- 3) C_2-C_{10} alkenyl,
- 30 4) C_2-C_{10} alkynyl,
- 5) $(C=O)_aO_b$ heterocyclyl,
- 6) $(C=O)_aO_bC_3-C_8$ cycloalkyl,
- 7) CO_2H ,
- 8) halo,
- 35 9) CN,

- 10) OH,
 11) $O_bC_1-C_6$ perfluoroalkyl,
 12) $O_a(C=O)_bNR^6R^7$,
 13) $NR^c(C=O)NR^6R^7$,
 5 14) $S(O)_mR^a$,
 15) $S(O)_2NR^6R^7$,
 16) $NR^cS(O)_mR^a$,
 17) CHO,
 18) NO_2 ,
 10 19) $NR^c(C=O)O_bR^a$,
 20) $O(C=O)O_bC_1-C_{10}$ alkyl,
 21) $O(C=O)O_bC_3-C_8$ cycloalkyl,
 22) $O(C=O)O_b$ aryl,
 23) $O(C=O)O_b$ -heterocycle, and
 15 24) $O_a-P=O(OH)_2$.

said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one, two or three substituents selected from R^Z ;

20 R^3 and R^4 are independently selected from: H, C_1-C_6 -alkyl and C_1-C_6 -perfluoroalkyl, or

R^3 and R^4 are combined to form $-(CH_2)_t-$ wherein one of the carbon atoms is optionally replaced by a moiety selected from O, $S(O)_m$, $-N(R^b)C(O)-$, and $-N(COR^a)-$;

25

R^5 is independently selected from:

- 1) H,
 2) $(C=O)_aO_bC_1-C_{10}$ alkyl,
 3) $(C=O)_aO_b$ aryl,
 30 4) C_2-C_{10} alkenyl,
 5) C_2-C_{10} alkynyl,
 6) $(C=O)_aO_b$ heterocyclyl,
 7) $(C=O)_aO_bC_3-C_8$ cycloalkyl,
 8) CO_2H ,
 35 9) halo,

- 10) CN,
- 11) OH,
- 12) $O_bC_1-C_6$ perfluoroalkyl,
- 13) $O_a(C=O)_bNR^6R^7$,
- 5 14) $NR^c(C=O)NR^6R^7$,
- 15) $S(O)_mR^a$,
- 16) $S(O)_2NR^6R^7$,
- 17) $NR^cS(O)_mR^a$,
- 18) oxo,
- 10 19) CHO,
- 20) NO_2 ,
- 21) $O(C=O)O_bC_1-C_{10}$ alkyl,
- 22) $O(C=O)O_bC_3-C_8$ cycloalkyl, and
- 23) $O_a-P=O(OH)_2$,
- 15 said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one or more substituents selected from R^Z ;

R^6 and R^7 are independently selected from:

- 1) H,
- 20 2) $(C=O)O_bR^a$,
- 3) C_1-C_{10} alkyl,
- 4) aryl,
- 5) C_2-C_{10} alkenyl,
- 6) C_2-C_{10} alkynyl,
- 25 7) heterocyclyl,
- 8) C_3-C_8 cycloalkyl,
- 9) SO_2R^a ,
- 10) $(C=O)NR^b_2$,
- 11) OH, and
- 30 12) $O_a-P=O(OH)_2$,

said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R^Z , or

R^6 and R^7 can be taken together with the nitrogen to which they are attached to form
35 a monocyclic or bicyclic heterocycle with 4-7 members in each ring and optionally

containing, in addition to the nitrogen, one or more additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one or more substituents selected from R^Z;

5 R^Z is selected from:

- 1) (C=O)_rO_s(C₁-C₁₀)alkyl,
- 2) O_r(C₁-C₃)perfluoroalkyl,
- 3) (C₀-C₆)alkylene-S(O)_mR^a,
- 4) oxo,
- 10 5) OH,
- 6) halo,
- 7) CN,
- 8) (C=O)_rO_s(C₂-C₁₀)alkenyl,
- 9) (C=O)_rO_s(C₂-C₁₀)alkynyl,
- 15 10) (C=O)_rO_s(C₃-C₆)cycloalkyl,
- 11) (C=O)_rO_s(C₀-C₆)alkylene-aryl,
- 12) (C=O)_rO_s(C₀-C₆)alkylene-heterocyclyl,
- 13) (C=O)_rO_s(C₀-C₆)alkylene-N(R^b)₂,
- 14) C(O)R^a,
- 20 15) (C₀-C₆)alkylene-CO₂R^a,
- 16) C(O)H,
- 17) (C₀-C₆)alkylene-CO₂H,
- 18) C(O)N(R^b)₂,
- 19) S(O)_mR^a,
- 25 20) S(O)₂N(R^b)₂
- 21) NR^c(C=O)O_bR^a,
- 22) O(C=O)O_bC₁-C₁₀ alkyl,
- 23) O(C=O)O_bC₃-C₈ cycloalkyl,
- 24) O(C=O)O_baryl,
- 30 25) O(C=O)O_b-heterocycle, and
- 26) O_a-P=O(OH)₂,

said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heterocyclyl is optionally substituted with up to three substituents selected from R^b, OH, (C₁-C₆)alkoxy, halogen, CO₂H, CN, O(C=O)C₁-C₆ alkyl, oxo, N(R^b)₂ and O_a-P=O(OH)₂;

R^a is: substituted or unsubstituted (C₁-C₆)alkyl, substituted or unsubstituted (C₂-C₆)alkenyl, substituted or unsubstituted (C₂-C₆)alkynyl, substituted or unsubstituted (C₃-C₆)cycloalkyl, substituted or unsubstituted aryl, (C₁-C₆)perfluoroalkyl, 2,2,2-trifluoroethyl, or substituted or unsubstituted heterocyclyl; and

R^b is: H, (C₁-C₆)alkyl, substituted or unsubstituted aryl, substituted or unsubstituted benzyl, substituted or unsubstituted heterocyclyl, (C₃-C₆)cycloalkyl, (C=O)OC₁-C₆alkyl, (C=O)C₁-C₆alkyl or S(O)₂ R^a ;


R^c is selected from:

- 1) H,
- 2) C₁-C₁₀ alkyl,
- 3) aryl,
- 4) C₂-C₁₀ alkenyl,
- 5) C₂-C₁₀ alkynyl,
- 6) heterocyclyl,
- 7) C₃-C₈ cycloalkyl, and
- 8) C₁-C₆ perfluoroalkyl,

said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R^Z , or

or a pharmaceutically acceptable salt or a stereoisomer thereof.

In a second embodiment of the instant invention is a compound as illustrated by Formula B:



wherein:

W=Y is selected from CR¹=N, N=CR¹;

all substituents and variables are as defined in the first embodiment;

5

or a pharmaceutically acceptable salt or a stereoisomer thereof.

In a third embodiment of the instant invention is a compound as illustrated by Formula B, wherein:

10

Q is selected from: -NR⁶R⁷, phenyl and heterocyclyl which are optionally substituted with one to three R^z;

R^a is: (C₁-C₆)alkyl, (C₃-C₆)cycloalkyl, aryl, or heterocyclyl; and

15


R^b is: H, (C₁-C₆)alkyl, aryl, heterocyclyl, (C₃-C₆)cycloalkyl, (C=O)OC₁-C₆ alkyl, (C=O)C₁-C₆ alkyl or S(O)₂R^a;

and all other substituents and variables are as defined in the second embodiment;

20

or a pharmaceutically acceptable salt or a stereoisomer thereof.

In a fourth embodiment of the instant invention is a compound illustrated by Formula C:



25

wherein:

Q is heterocyclyl, said heterocyclyl optionally substituted with 1 to 3 R^z;

R² is independently selected from:

- 1) C₁-C₆ alkyl,
- 2) aryl,
- 5 3) heterocyclyl,
- 4) CO₂H,
- 5) halo,
- 6) CN,
- 7) OH,
- 10 8) S(O)₂NR⁶R⁷, and
- 9) O_a-P=O(OH)₂,

said alkyl, aryl and heterocyclyl optionally substituted with one, two or three substituents selected from R^Z;

15 and all other substituents and variables are as defined in the third embodiment;

or a pharmaceutically acceptable salt or a stereoisomer thereof.

Specific compounds of the instant invention include:

20

1-(1-{4-[3-(1,3-oxazol-2-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;

25

1-{1-[4-(6-phenyl-3-pyrimidin-2-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;

1-(1-{4-[3-(1H-imidazol-2-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;

30

1-(1-{4-[3-(1-methyl-1H-pyrazol-5-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;

1-(1-{4-[6-phenyl-3-(1H-pyrazol-5-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;

35

- 13 -

- 1-(1-{4-[6-phenyl-3-(1,3-thiazol-2-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;
- 5 1-(1-{4-[6-phenyl-3-(1,3-thiazol-5-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;
- 1-(1-{4-[6-phenyl-3-(1H-1,2,3-triazol-5-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;
- 10 1-(1-{4-[6-phenyl-3-(1,3-thiazol-4-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;
- 1-(1-{4-[3-(1,1'-biphenyl-4-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;
- 15 1-{1-[4-(2-methyl-3-oxo-6-phenyl-2,3-dihydro-1,2,4-triazin-5-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;
- 20 1-{1-[4-(2-methyl-3-oxo-5-phenyl-2,3-dihydro-1,2,4-triazin-6-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; and
- 1-(1-{4-[3-(methylthio)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;
- 25 or a pharmaceutically acceptable salt or a stereoisomer thereof.

Specific TFA salts of the compounds of the instant invention include:

- 30 1-(1-{4-[3-(1,3-oxazol-2-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;
- 1-(1-{4-[6-phenyl-3-pyrimidin-2-yl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;

35

- 1-(1-{4-[3-(1H-imidazol-2-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;
- 5 1-(1-{4-[3-(1-methyl-1H-pyrazol-5-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;
- 1-(1-{4-[6-phenyl-3-(1H-pyrazol-5-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;
- 10 1-(1-{4-[6-phenyl-3-(1H-pyrazol-5-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;
- 1-(1-{4-[3-(1-methyl-1H-pyrazol-4-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;
- 15 1-(1-{4-[3-(1-methyl-1H-imidazol-2-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;
- 1-{1-[4-(6-phenyl-3-tetrahydrofuran-3-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;
- 20 1-{1-[4-(6-phenyl-3-tetrahydrofuran-2-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;
- 25 1-{1-[4-(6-phenyl-3-thien-2-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;
- 1-(1-{4-[3-(4-methylmorpholin-3-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;
- 30 1-(1-{4-[3-(1-acetylazetid-3-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;
- 1-{1-[4-(6-phenyl-3-pyridin-2-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;
- 35

5 1-{1-[4-(6-phenyl-3-pyridin-4-yl-1,2,4-triazin-5-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;

10

15

20

25

30

35

or a stereoisomer thereof.

In a further embodiment, specific compounds of the instant invention include:


- 5 1-{1-[4-(6-phenyl-3-pyrimidin-2-yl-1,2,4-triazin-5-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;
- 1-(1-{4-[6-phenyl-3-(1H-1,2,3-triazol-5-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;
- 10 1-(1-{4-[6-phenyl-3-(1,3-thiazol-4-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one; and
- 15 1-(1-{4-[3-(1,1'-biphenyl-4-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;

or a pharmaceutically acceptable salt or a stereoisomer thereof.


20 The compounds of the present invention may have asymmetric centers, chiral axes, and chiral planes (as described in: E.L. Eliel and S.H. Wilen, *Stereochemistry of Carbon Compounds*, John Wiley & Sons, New York, 1994, pages 1119-1190), and occur as racemates, racemic mixtures, and as individual diastereomers, with all possible isomers and mixtures thereof, including optical isomers, all such stereoisomers being included in the present invention.

25 In addition, the compounds disclosed herein may exist as tautomers and both tautomeric forms are intended to be encompassed by the scope of the invention, even though only one tautomeric structure is depicted. For example, any claim to compound A below is understood to include tautomeric structure B, and vice versa, as well as mixtures thereof. The two tautomeric forms of the benzimidazolonyl moiety are also within the scope of the instant invention.

30



Tetrazoles exist as a mixture of 1H/2H tautomers. The tautomeric
 5 forms of the tetrazol moiety are also within the scope of the instant invention.



When any variable (e.g. R¹, R², R^Z, etc.) occurs more than one time
 in any constituent, its definition on each occurrence is independent at every other
 10 occurrence. Also, combinations of substituents and variables are permissible only
 if such combinations result in stable compounds. Lines drawn into the ring systems
 from substituents represent that the indicated bond may be attached to any of the
 substitutable ring atoms. If the ring system is polycyclic, it is intended that the
 bond be attached to any of the suitable carbon atoms on the proximal ring only.

15 It is understood that substituents and substitution patterns on the
 compounds of the instant invention can be selected by one of ordinary skill in the art
 to provide compounds that are chemically stable and that can be readily synthesized
 by techniques known in the art, as well as those methods set forth below, from readily
 available starting materials. If a substituent is itself substituted with more than one
 20 group, it is understood that these multiple groups may be on the same carbon or
 on different carbons, so long as a stable structure results. The phrase "optionally
 substituted with one or more substituents" should be taken to be equivalent to the
 phrase "optionally substituted with at least one substituent" and in such cases an

As used herein, "alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. For example, C₁-C₁₀, as in "C₁-C₁₀ alkyl" is defined to include groups having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbons in a linear or branched arrangement. For example, "C₁-C₁₀ alkyl" specifically includes methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *t*-butyl, *i*-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, and so on. The term "cycloalkyl" means a monocyclic saturated aliphatic hydrocarbon group having the specified number of carbon atoms. For example, "cycloalkyl" includes cyclopropyl, methyl-cyclopropyl, 2,2-dimethyl-cyclobutyl, 2-ethyl-cyclopentyl, cyclohexyl, and so on.

"Alkoxy" represents either a cyclic or non-cyclic alkyl group of indicated number of carbon atoms attached through an oxygen bridge. "Alkoxy" therefore encompasses the definitions of alkyl and cycloalkyl above.

If no number of carbon atoms is specified, the term “alkenyl” refers to a non-aromatic hydrocarbon radical, straight, branched or cyclic, containing from 2 to 10 carbon atoms and at least one carbon to carbon double bond. In an embodiment, one carbon to carbon double bond is present, and up to four non-aromatic carbon-carbon double bonds may be present. Thus, “C₂-C₆ alkenyl” means an alkenyl radical having from 2 to 6 carbon atoms. Alkenyl groups include ethenyl, propenyl, butenyl, 2-methylbutenyl and cyclohexenyl. The straight, branched or cyclic portion of the alkenyl group may contain double bonds and may be substituted if a substituted alkenyl group is indicated.

25 The term “alkynyl” refers to a hydrocarbon radical straight,
branched or cyclic, containing from 2 to 10 carbon atoms and at least one carbon
to carbon triple bond. Up to three carbon-carbon triple bonds may be present. Thus,
“C₂-C₆ alkynyl” means an alkynyl radical having from 2 to 6 carbon atoms. Alkynyl
groups include ethynyl, propynyl, butynyl, 3-methylbutynyl and so on. The straight,
30 branched or cyclic portion of the alkynyl group may contain triple bonds and may be
substituted if a substituted alkynyl group is indicated.

- 19 -

5


10

30


35

As used herein, unless otherwise specifically defined, substituted alkyl, substituted cycloalkyl, substituted aroyl, substituted aryl, substituted heteroaroyl, substituted heteroaryl, substituted arylsulfonyl, substituted heteroaryl-sulfonyl and substituted heterocycle include moieties containing from 1 to 4 substituents (and in another embodiment 1 to 3 substituents) in addition to the point of attachment to the rest of the compound. Such substituents are selected from the group which includes but is not limited to F, Cl, Br, CF₃, NH₂, N(C₁-C₆ alkyl)₂, NO₂, CN, (C₁-C₆ alkyl)O-, (aryl)O-, -OH, O_a-P=O(OH)₂, (C₁-C₆ alkyl)S(O)_m-, (C₁-C₆ alkyl)C(O)NH-, H₂N-C(NH)-, (C₁-C₆ alkyl)C(O)-, (C₁-C₆ alkyl)OC(O)-, (C₁-C₆ alkyl)OC(O)NH-, phenyl, pyridyl, imidazolyl, oxazolyl, isoxazolyl, tetrazolyl, thiazolyl, thienyl, furyl, isothiazolyl and C₁-C₂₀ alkyl. For example, a (C₁-C₆)alkyl may be substituted with one, two, three or four (in another embodiment one, two or three) substituents selected from OH, oxo, halogen, alkoxy, dialkylamino, or heterocyclyl, such as morpholinyl, piperidinyl, and so on. In this case, if one substituent is oxo and the other is OH, the following are included in the definition: - (C=O)CH₂CH(OH)CH₃; -(C=O)OH, -CH₂(OH)CH₂CH(O), and so on.

In the Formula A, the moiety illustrated by the formula:



includes the following structures, which are meant to be merely illustrative and not limiting:




The moiety formed when, in the definition of R³ and R⁴ on the same carbon atom are combined to form -(CH₂)_t- is illustrated by the following:




In addition, such cyclic moieties may optionally include a heteroatom(s). Examples of such heteroatom-containing cyclic moieties include, but are not limited to:

5



In certain instances, R^6 and R^7 are defined such that they can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 4-7 members in each ring and optionally containing, in addition to the nitrogen, one or more additional heteroatoms selected from N, O and S, said heterocycle optionally substituted with one or more substituents selected from R^Z . Examples of the heterocycles that can thus be formed include, but are not limited to the following, keeping in mind that the heterocycle is optionally substituted with one or more (and in another embodiment one, two or three) substituents chosen from R^Z :

15



In another embodiment, p is 0.

In another embodiment, R^a is (C_1-C_6) alkyl.


5

In another embodiment, R^b is independently H, (C_1-C_6) alkyl, $(C=O)O(C_1-C_6)$ alkyl, $(C=O)(C_1-C_6)$ alkyl or $S(O)_2R^a$.

In another embodiment, R^z is selected from halogen, CN, OH, $O_a-P=O(OH)_2$, oxo, C_1-C_6 alkyl, $S(O)_mR^a$, $(C=O)_rO_s(C_1-C_6)$ alkyl and phenyl.

In another embodiment, $R^{1'}$ is selected from C_1 - C_6 alkyl and $S(O)_mRa$.

In another embodiment, R^1 is selected from C_1 - C_6 alkyl, C_1 - C_6 alkyl-heterocyclyl, halogen, CN, phenyl, OH, $O_a-P=O(OH)_2$, oxo and heterocyclyl, said
 5 heterocyclyl is selected from:



optionally substituted with one to three substituents selected from R^Z , wherein R^Z is selected from C_1 - C_6 alkyl, phenyl and $-(C=O)(C_1-C_6)alkyl$.

10 In another embodiment, R^3 and R^4 are selected from H and $-CH_3$.


In another embodiment, R^3 and R^4 are selected from H.

In another embodiment, R^6 and R^7 are selected from H, C_1 - C_6 alkyl and aryl, optionally substituted with one to two substituents selected from R^Z , or R^6
 15 and R^7 together with the nitrogen to which they are attached form a monocyclic or bicyclic heterocycle, optionally substituted with one to two substituents selected from R^Z .

In another embodiment, R⁶ and R⁷ are selected from H or C₁-C₆ alkyl, or R⁶ and R⁷ together with the nitrogen to which they are attached form a monocyclic or bicyclic heterocycle, optionally substituted with one to two substituents selected from R^z.

5

In another embodiment, Q is selected from:



Included in the instant invention is the free form of compounds of Formula A, as well as the pharmaceutically acceptable salts and stereoisomers thereof. Some of the isolated specific compounds exemplified herein are the protonated salts of amine compounds. The term "free form" refers to the amine compounds in non-salt form. The encompassed pharmaceutically acceptable salts not only include the isolated salts exemplified for the specific compounds described herein, but also all the typical pharmaceutically acceptable salts of the free form of compounds of Formula A. The free form of the specific salt compounds described may be isolated using techniques known in the art. For example, the free form may be regenerated by treating the salt with a suitable dilute aqueous base solution such as dilute aqueous NaOH, potassium carbonate, ammonia and sodium bicarbonate. The free forms may differ from their respective salt forms somewhat in certain physical properties, such as solubility in polar solvents, but the acid and base salts are otherwise pharmaceutically equivalent to their respective free forms for purposes of the invention.

The pharmaceutically acceptable salts of the instant compounds can be synthesized from the compounds of this invention which contain a basic or acidic moiety by conventional chemical methods. Generally, the salts of the basic compounds are prepared either by ion exchange chromatography or by reacting the free base with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid in a suitable solvent or various combinations of solvents. Similarly, the salts of the acidic compounds are formed by reactions with the appropriate inorganic or organic base.

Thus, pharmaceutically acceptable salts of the compounds of this invention include the conventional non-toxic salts of the compounds of this invention as formed by reacting a basic instant compound with an inorganic or organic acid. For example, conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like, as well as salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pantoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, trifluoroacetic (TFA) and the like.

When the compound of the present invention is acidic, suitable "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like.

The preparation of the pharmaceutically acceptable salts described above and other typical pharmaceutically acceptable salts is more fully described by Berg *et al.*, "Pharmaceutical Salts," *J. Pharm. Sci.*, 1977:66:1-19.

It will also be noted that the compounds of the present invention are potentially internal salts or zwitterions, since under physiological conditions a deprotonated acidic moiety in the compound, such as a carboxyl group, may be anionic, and this electronic charge might then be balanced off internally against the cationic charge of a protonated or alkylated basic moiety, such as a quaternary nitrogen atom.

10

25

35

Further included within the scope of the invention is a method of treating or preventing a disease in which angiogenesis is implicated, which is comprised of administering to a mammal in need of such treatment a therapeutically effective amount of a compound of the present invention. Ocular neovascular diseases are an example of conditions where much of the resulting tissue damage can be attributed to aberrant infiltration of blood vessels in the eye (see WO 00/30651, published 2 June 2000). The undesirable infiltration can be triggered by ischemic retinopathy, such as that resulting from diabetic retinopathy, retinopathy of prematurity, retinal vein occlusions, etc., or by degenerative diseases, such as the choroidal neovascularization observed in age-related macular degeneration. Inhibiting the growth of blood vessels by administration of the present compounds would therefore prevent the infiltration of blood vessels and prevent or treat diseases where angiogenesis is implicated, such as ocular diseases like retinal vascularization, diabetic retinopathy, age-related macular degeneration, and the like.

Further included within the scope of the invention is a method of treating or preventing a non-malignant disease in which angiogenesis is implicated, including but not limited to: ocular diseases (such as, retinal vascularization, diabetic retinopathy and age-related macular degeneration), atherosclerosis, arthritis, psoriasis, obesity and Alzheimer's disease (Dredge et al., *Expert Opin. Biol. Ther.* (2002) 2(8):953-966). In another embodiment, a method of treating or preventing a disease in which angiogenesis is implicated includes: ocular diseases (such as, retinal vascularization, diabetic retinopathy and age-related macular degeneration), atherosclerosis, arthritis and psoriasis.

Further included within the scope of the invention is a method of treating hyperproliferative disorders such as restenosis, inflammation, autoimmune diseases and allergy/asthma.

Further included within the scope of the invention is a method of treating hyperinsulinism.

In an embodiment of the invention, the instant compound is a selective inhibitor whose inhibitory efficacy is dependent on the PH domain. In this embodiment, the compound exhibits a decrease in *in vitro* inhibitory activity or no *in vitro* inhibitory activity against truncated Akt proteins lacking the PH domain.

In a further embodiment, the instant compound is selected from the group of a selective inhibitor of Akt1, a selective inhibitor of Akt2 and a selective inhibitor of both Akt1 and Akt2.

In another embodiment, the instant compound is selected from the group of a selective inhibitor of Akt1, a selective inhibitor of Akt2, a selective inhibitor of Akt3 and a selective inhibitor of two of the three Akt isoforms.

5 In another embodiment, the instant compound is a selective inhibitor of all three Akt isoforms, but is not an inhibitor of one, two or all of such Akt isoforms that have been modified to delete the PH domain, the hinge region or both the PH domain and the hinge region.

The present invention is further directed to a method of inhibiting Akt activity which comprises administering to a mammal in need thereof a
10 pharmaceutically effective amount of the instant compound.

The compounds of this invention may be administered to mammals, preferably humans, either alone or, preferably, in combination with pharmaceutically acceptable carriers, excipients or diluents, in a pharmaceutical composition, according to standard pharmaceutical practice. The compounds can be
15 administered orally or parenterally, including the intravenous, intramuscular, intraperitoneal, subcutaneous, rectal and topical routes of administration.

The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules,
20 or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the
25 active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, microcrystalline cellulose, sodium crosscarmellose, corn starch, or alginic
30 acid; binding agents, for example starch, gelatin, polyvinyl-pyrrolidone or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to mask the unpleasant taste of the drug or delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a water soluble
35 taste masking material such as hydroxypropylmethyl-cellulose or

hydroxypropylcellulose, or a time delay material such as ethyl cellulose, cellulose acetate butyrate may be employed.

Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water soluble carrier such as polyethyleneglycol or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene-oxyctanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as butylated hydroxyanisol or alpha-tocopherol.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example

sweetening, flavoring and coloring agents, may also be present. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

The pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring phosphatides, for example soy bean lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening, 10 flavouring agents, preservatives and antioxidants.

Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, flavoring and coloring agents and antioxidant.

15 The pharmaceutical compositions may be in the form of a sterile injectable aqueous solutions. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.

The sterile injectable preparation may also be a sterile injectable oil-in-water microemulsion where the active ingredient is dissolved in the oily phase. For 20 example, the active ingredient may be first dissolved in a mixture of soybean oil and lecithin. The oil solution then introduced into a water and glycerol mixture and processed to form a microemulsion.

The injectable solutions or microemulsions may be introduced into a patient's blood-stream by local bolus injection. Alternatively, it may be advantageous 25 to administer the solution or microemulsion in such a way as to maintain a constant circulating concentration of the instant compound. In order to maintain such a constant concentration, a continuous intravenous delivery device may be utilized. An example of such a device is the Deltec CADD-PLUS™ model 5400 intravenous pump.

30 The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension for intramuscular and subcutaneous administration. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a 35 sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent

or solvent, for example as a solution in 1,3-butane diol. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

5 Compounds of Formula A may also be administered in the form of a suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials include cocoa butter, glycerinated
10 gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol.

For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compound of Formula A are employed. (For purposes of this application, topical application shall include mouth washes and gargles.)

15 The compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles and delivery devices, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in the art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than
20 intermittent throughout the dosage regimen.

As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specific amounts, as well as any product which results, directly or indirectly, from combination of the specific ingredients in the specified amounts.

25 Additionally, the compounds of the instant invention may be administered to a mammal in need thereof using a gel extrusion mechanism (GEM) device, such as that described in U.S. Patent No. 4,976,697, filed on December 11, 1990, which is hereby incorporated by reference.

30 The instant compounds are also useful in combination with known therapeutic agents and anti-cancer agents. For example, instant compounds are useful in combination with known anti-cancer agents. Combinations of the presently disclosed compounds with other anti-cancer or chemotherapeutic agents are within the scope of the invention. Examples of such agents can be found in *Cancer Principles and Practice of Oncology* by V.T. Devita and S. Hellman (editors), 6th edition
35 (February 15, 2001), Lippincott Williams & Wilkins Publishers. A person of ordinary

5

10

15

25

30

35

kinases involved in mitotic progression, inhibitors of kinases involved in growth factor and cytokine signal transduction pathways, antimetabolites, biological response modifiers, hormonal/anti-hormonal therapeutic agents, haematopoietic growth factors, monoclonal antibody targeted therapeutic agents, topoisomerase inhibitors, proteasome inhibitors and ubiquitin ligase inhibitors..

Examples of cytotoxic/cytostatic agents include, but are not limited to, sertenef, cachectin, ifosfamide, tasonermin, lonidamine, carboplatin, altretamine, prednimustine, dibromodulcitol, ranimustine, fotemustine, nedaplatin, oxaliplatin, temozolomide, heptaplatin, estramustine, improsulfan tosilate, trofosfamide, nimustine, dibrospidium chloride, pumitepa, lobaplatin, satraplatin, profiromycin, cisplatin, irofulven, dexifosfamide, cis-aminedichloro(2-methyl-pyridine)platinum, benzylguanine, glufosfamide, GPX100, (trans, trans, trans)-bis-mu-(hexane-1,6-diamine)-mu-[diamine-platinum(II)]bis[diamine(chloro)platinum (II)]tetrachloride, diarizidinylspermine, arsenic trioxide, 1-(11-dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine, zorubicin, idarubicin, daunorubicin, bisantrene, mitoxantrone, pirarubicin, pinafide, valrubicin, amrubicin, antineoplaston, 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin, annamycin, galarubicin, elinafide, MEN10755, 4-demethoxy-3-deamino-3-aziridinyl-4-methylsulphonyl-daunorubicin (see WO 00/50032), Raf kinases inhibitors (such as Bay43-9006) and mTOR inhibitors (such as Wyeth's CCI-779).

An example of a hypoxia activatable compound is tirapazamine.

Examples of proteasome inhibitors include but are not limited to lactacystin and MLN-341 (Velcade):

Examples of microtubule inhibitors/microtubule-stabilising agents include paclitaxel, vindesine sulfate, 3',4'-didehydro-4'-deoxy-8'-norvincal leukoblastine, docetaxol, rhizoxin, dolastatin, mivobulin isethionate, auristatin, cemadotin, RPR109881, BMS184476, vinflunine, cryptophycin, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl) benzene sulfonamide, anhydrovinblastine, N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-L-proline-t-butylamide, TDX258, the epothilones (see for example U.S. Pat. Nos. 6,284,781 and 6,288,237) and BMS188797. In an embodiment the epothilones are not included in the microtubule inhibitors/microtubule-stabilising agents.

Some examples of topoisomerase inhibitors are topotecan, hycaptamine, irinotecan, rubitecan, 6-ethoxypropionyl-3',4'-O-exo-benzylidene-chartreusin, 9-methoxy-N,N-dimethyl-5-nitropyrzolo[3,4,5-kl]acridine-2-(6H)

propanamine, 1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano[3',4':b,7]-indolizino[1,2b]quinoline-10,13(9H,15H)dione, lurtotecan, 7-[2-(N-isopropylamino)ethyl]-(20S)camptothecin, BNP1350, BNPI1100, BN80915, BN80942, etoposide phosphate, teniposide, sobuzoxane, 2'-
5 dimethylamino-2'-deoxy-etoposide, GL331, N-[2-(dimethylamino)ethyl]-9-hydroxy-5,6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxamide, asulacrine, (5a, 5aB, 8aa,9b)-9-[2-[N-[2-(dimethylamino)ethyl]-N-methylamino]ethyl]-5-[4-hydroxy-3,5-dimethoxyphenyl]-5,5a,6,8,8a,9-hexahydrofuro(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6-one, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]-
10 phenanthridinium, 6,9-bis[(2-aminoethyl)amino]benzo[g]isoguinoline-5,10-dione, 5-(3-aminopropylamino)-7,10-dihydroxy-2-(2-hydroxyethylaminomethyl)-6H-pyrazolo[4,5,1-de]acridin-6-one, N-[1-[2(diethylamino)ethylamino]-7-methoxy-9-oxo-9H-thioxanthen-4-ylmethyl]formamide, N-(2-(dimethylamino)ethyl)acridine-4-carboxamide, 6-[[2-(dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]
15 quinolin-7-one, and dimesna.

Examples of inhibitors of mitotic kinesins, and in particular the human mitotic kinesin KSP, are described in PCT Publications WO 01/30768 and WO 01/98278, and pending U.S. Ser. Nos. 60/338,779 (filed December 6, 2001), 60/338,344 (filed December 6, 2001), 60/338,383 (filed December 6, 2001),
20 60/338,380 (filed December 6, 2001), 60/338,379 (filed December 6, 2001) and 60/344,453 (filed November 7, 2001). In an embodiment inhibitors of mitotic kinesins include, but are not limited to inhibitors of KSP, inhibitors of MKLP1, inhibitors of CENP-E, inhibitors of MCAK and inhibitors of Rab6-KIFL.

"Inhibitors of kinases involved in mitotic progression" include, but are
25 not limited to, inhibitors of aurora kinase, inhibitors of Polo-like kinases (PLK; in particular inhibitors of PLK-1), inhibitors of bub-1 and inhibitors of bub-R1.


"Antiproliferative agents" includes antisense RNA and DNA oligonucleotides such as G3139, ODN698, RVASKRAS, GEM231, and INX3001, and antimetabolites such as enocitabine, carmofur, tegafur, pentostatin, doxifluridine,
30 trimetrexate, fludarabine, capecitabine, galocitabine, cytarabine ocfosfate, fosteabine sodium hydrate, raltitrexed, paltitrexid, emitefur, tiazofurin, decitabine, nolatrexed, pemetrexed, nelzarabine, 2'-deoxy-2'-methylidenecytidine, 2'-fluoromethylene-2'-deoxycytidine, N-[5-(2,3-dihydro-benzofuryl)sulfonyl]-N'-(3,4-dichlorophenyl)urea, N6-[4-deoxy-4-[N2-[2(E),4(E)-tetradecadienoyl]glycylamino]-L-glycero-B-L-manno-
35 heptopyranosyl]adenine, aplidine, ecteinascidin, troxacitabine, 4-[2-amino-4-oxo-

5 methioninase, 2'-cyano-2'-deoxy-N4-palmitoyl-1-B-D-arabino furanosyl cytosine, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone and trastuzumab.

10 Веххат.

15 84/02131 at pp. 30-33. The terms “HMG-CoA reductase inhibitor” and “inhibitor of HMG-CoA reductase” have the same meaning when used herein.

20 4,820,850 and 4,916,239), pravastatin (PRAVACHOL®; see U.S. Patent Nos. 4,346,227, 4,537,859, 4,410,629, 5,030,447 and 5,180,589), fluvastatin (LESCOL®; see U.S. Patent Nos. 5,354,772, 4,911,165, 4,929,437, 5,189,164, 5,118,853, 5,290,946 and 5,356,896), atorvastatin (LIPITOR®; see U.S. Patent Nos. 5,273,995, 4,681,893, 5,489,691 and 5,342,952) and cerivastatin (also known as rivastatin and
25 BAYCHOL®; see US Patent No. 5,177,080). The structural formulas of these and additional HMG-CoA reductase inhibitors that may be used in the instant methods are described at page 87 of M. Yalpani, "Cholesterol Lowering Drugs", *Chemistry & Industry*, pp. 85-89 (5 February 1996) and US Patent Nos. 4,782,084 and 4,885,314. The term HMG-CoA reductase inhibitor as used herein includes all pharmaceutically
30 acceptable lactone and open-acid forms (i.e., where the lactone ring is opened to form the free acid) as well as salt and ester forms of compounds which have HMG-CoA reductase inhibitory activity, and therefor the use of such salts, esters, open-acid and lactone forms is included within the scope of this invention. An illustration of the lactone portion and its corresponding open-acid form is shown below as structures I
35 and II.



In HMG-CoA reductase inhibitors where an open-acid form can exist, salt and ester forms may be formed from the open-acid, and all such forms are included within the meaning of the term "HMG-CoA reductase inhibitor" as used herein. In an embodiment, the HMG-CoA reductase inhibitor is selected from lovastatin and simvastatin, and in a further embodiment, simvastatin. Herein, the term "pharmaceutically acceptable salts" with respect to the HMG-CoA reductase inhibitor shall mean non-toxic salts of the compounds employed in this invention which are generally prepared by reacting the free acid with a suitable organic or inorganic base, particularly those formed from cations such as sodium, potassium, aluminum, calcium, lithium, magnesium, zinc and tetramethylammonium, as well as those salts formed from amines such as ammonia, ethylenediamine, N-methylglucamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, 1-p-chlorobenzyl-2-pyrrolidine-1'-yl-methylbenz-imidazole, diethylamine, piperazine, and tris(hydroxymethyl) aminomethane. Further examples of salt forms of HMG-CoA reductase inhibitors may include, but are not limited to, acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycolylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynapthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylsulfate, mucate, napsylate, nitrate, oleate, oxalate, pamaote, palmitate, panthothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, tannate, tartrate, teoclate, tosylate, triethiodide, and valerate.

Ester derivatives of the described HMG-CoA reductase inhibitor compounds may act as prodrugs which, when absorbed into the bloodstream of a

warm-blooded animal, may cleave in such a manner as to release the drug form and permit the drug to afford improved therapeutic efficacy.

"Prenyl-protein transferase inhibitor" refers to a compound which inhibits any one or any combination of the prenyl-protein transferase enzymes, including farnesyl-protein transferase (FPTase), geranylgeranyl-protein transferase type I (GGPTase-I), and geranylgeranyl-protein transferase type-II (GGPTase-II, also called Rab GGPTase). Examples of prenyl-protein transferase inhibiting compounds include (+)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone, (-)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone, (+)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone, 5(S)-n-butyl-1-(2,3-dimethylphenyl)-4-[1-(4-cyanobenzyl)-5-imidazolylmethyl]-2-piperazinone, (S)-1-(3-chlorophenyl)-4-[1-(4-cyanobenzyl)-5-imidazolylmethyl]-5-[2-(ethanesulfonyl)methyl]-2-piperazinone, 5(S)-n-Butyl-1-(2-methylphenyl)-4-[1-(4-cyanobenzyl)-5-imidazolylmethyl]-2-piperazinone, 1-(3-chlorophenyl)-4-[1-(4-cyanobenzyl)-2-methyl-5-imidazolylmethyl]-2-piperazinone, 1-(2,2-diphenylethyl)-3-[N-(1-(4-cyanobenzyl)-1H-imidazol-5-ylethyl)carbamoyl]piperidine, 4-{5-[4-hydroxymethyl-4-(4-chloropyridin-2-ylmethyl)-piperidine-1-ylmethyl]-2-methylimidazol-1-ylmethyl} benzonitrile, 4-{5-[4-hydroxymethyl-4-(3-chlorobenzyl)-piperidine-1-ylmethyl]-2-methylimidazol-1-ylmethyl} benzonitrile, 4-{3-[4-(2-oxo-2H-pyridin-1-yl)benzyl]-3H-imidazol-4-ylmethyl} benzonitrile, 4-{3-[4-(5-chloro-2-oxo-2H-[1,2']bipyridin-5'-ylmethyl)-3H-imidazol-4-ylmethyl} benzonitrile, 4-{3-[4-(2-oxo-2H-[1,2']bipyridin-5'-ylmethyl)-3H-imidazol-4-ylmethyl} benzonitrile, 4-[3-(2-oxo-1-phenyl-1,2-dihydropyridin-4-ylmethyl)-3H-imidazol-4-ylmethyl} benzonitrile, 18,19-dihydro-19-oxo-5H,17H-6,10:12,16-dimetheno-1H-imidazo[4,3-c][1,11,4]dioxazacyclononadecine-9-carbonitrile, (±)-19,20-dihydro-19-oxo-5H-18,21-ethano-12,14-etheno-6,10-metheno-22H-benzo[d]imidazo[4,3-k][1,6,9,12]oxatriaza-cyclooctadecine-9-carbonitrile, 19,20-dihydro-19-oxo-5H,17H-18,21-ethano-6,10:12,16-dimetheno-22H-imidazo[3,4-h][1,8,11,14]oxatriazacycloicosine-9-carbonitrile, and (±)-19,20-dihydro-3-methyl-19-oxo-5H-18,21-ethano-12,14-etheno-6,10-metheno-22H-benzo[d]imidazo[4,3-k][1,6,9,12]oxa-triazacyclooctadecine-9-carbonitrile.

Other examples of prenyl-protein transferase inhibitors can be found in the following publications and patents: WO 96/30343, WO 97/18813, WO 97/21701, WO 97/23478, WO 97/38665, WO 98/28980, WO 98/29119, WO 95/32987, U.S.

- Patent No. 5,420,245, U.S. Patent No. 5,523,430, U.S. Patent No. 5,532,359, U.S. Patent No. 5,510,510, U.S. Patent No. 5,589,485, U.S. Patent No. 5,602,098, European Patent Publ. 0 618 221, European Patent Publ. 0 675 112, European Patent Publ. 0 604 181, European Patent Publ. 0 696 593, WO 94/19357, WO 95/08542,
- 5 WO 95/11917, WO 95/12612, WO 95/12572, WO 95/10514, U.S. Patent No. 5,661,152, WO 95/10515, WO 95/10516, WO 95/24612, WO 95/34535, WO 95/25086, WO 96/05529, WO 96/06138, WO 96/06193, WO 96/16443, WO 96/21701, WO 96/21456, WO 96/22278, WO 96/24611, WO 96/24612, WO 96/05168, WO 96/05169, WO 96/00736, U.S. Patent No. 5,571,792,
- 10 WO 96/17861, WO 96/33159, WO 96/34850, WO 96/34851, WO 96/30017, WO 96/30018, WO 96/30362, WO 96/30363, WO 96/31111, WO 96/31477, WO 96/31478, WO 96/31501, WO 97/00252, WO 97/03047, WO 97/03050, WO 97/04785, WO 97/02920, WO 97/17070, WO 97/23478, WO 97/26246, WO 97/30053, WO 97/44350, WO 98/02436, and U.S. Patent No. 5,532,359.
- 15 For an example of the role of a prenyl-protein transferase inhibitor on angiogenesis see European J. of Cancer, Vol. 35, No. 9, pp.1394-1401 (1999).

“Angiogenesis inhibitors” refers to compounds that inhibit the formation of new blood vessels, regardless of mechanism. Examples of angiogenesis inhibitors include, but are not limited to, tyrosine kinase inhibitors, such as inhibitors

20 of the tyrosine kinase receptors Flt-1 (VEGFR1) and Flk-1/KDR (VEGFR2), inhibitors of epidermal-derived, fibroblast-derived, or platelet derived growth factors, MMP (matrix metalloprotease) inhibitors, integrin blockers, interferon- α , interleukin-12, pentosan polysulfate, cyclooxygenase inhibitors, including nonsteroidal anti-inflammatories (NSAIDs) like aspirin and ibuprofen as well as selective cyclooxygenase-2 inhibitors like celecoxib and rofecoxib (*PNAS*, Vol. 89, p. 7384 (1992); *JNCI*, Vol. 69, p. 475 (1982); *Arch. Ophthalmol.*, Vol. 108, p.573 (1990); *Anat. Rec.*, Vol. 238, p. 68 (1994); *FEBS Letters*, Vol. 372, p. 83 (1995); *Clin. Orthop.* Vol. 313, p. 76 (1995); *J. Mol. Endocrinol.*, Vol. 16, p.107 (1996); *Jpn. J. Pharmacol.*, Vol. 75, p. 105 (1997); *Cancer Res.*, Vol. 57, p. 1625 (1997); *Cell*, Vol. 93, p. 705 (1998);

30 *Intl. J. Mol. Med.*, Vol. 2, p. 715 (1998); *J. Biol. Chem.*, Vol. 274, p. 9116 (1999)), steroidal anti-inflammatories (such as corticosteroids, mineralocorticoids, dexamethasone, prednisone, prednisolone, methylpred, betamethasone), carboxyamidotriazole, combretastatin A-4, squalamine, 6-O-chloroacetyl-carbonyl-fumagillol, thalidomide, angiostatin, troponin-1, angiotensin II antagonists (see

35 Fernandez et al., *J. Lab. Clin. Med.* 105:141-145 (1985)), and antibodies to VEGF

(see, *Nature Biotechnology*, Vol. 17, pp.963-968 (October 1999); Kim et al., *Nature*, 362, 841-844 (1993); WO 00/44777; and WO 00/61186).

Other therapeutic agents that modulate or inhibit angiogenesis and may also be used in combination with the compounds of the instant invention include
5 agents that modulate or inhibit the coagulation and fibrinolysis systems (see review in *Clin. Chem. La. Med.* 38:679-692 (2000)). Examples of such agents that modulate or inhibit the coagulation and fibrinolysis pathways include, but are not limited to, heparin (see *Thromb. Haemost.* 80:10-23 (1998)), low molecular weight heparins and carboxypeptidase U inhibitors (also known as inhibitors of active thrombin activatable
10 fibrinolysis inhibitor [TAFIa]) (see *Thrombosis Res.* 101:329-354 (2001)). TAFIa inhibitors have been described in U.S. Ser. Nos. 60/310,927 (filed August 8, 2001) and 60/349,925 (filed January 18, 2002).

“Agents that interfere with cell cycle checkpoints” refer to compounds that inhibit protein kinases that transduce cell cycle checkpoint signals, thereby
15 sensitizing the cancer cell to DNA damaging agents. Such agents include inhibitors of ATR, ATM, the Chk1 and Chk2 kinases and cdk and cdc kinase inhibitors and are specifically exemplified by 7-hydroxystaurosporin, flavopiridol, CYC202 (Cyclacel) and BMS-387032.

“Inhibitors of cell proliferation and survival signalling pathway” refer
20 to compounds that inhibit signal transduction cascades downstream of cell surface receptors. Such agents include inhibitors of serine/threonine kinases (including but not limited to inhibitors of Akt such as described in WO 02/083064, WO 02/083139, WO 02/083140 and WO 02/083138), inhibitors of Raf kinase (for example BAY-43-9006), inhibitors of MEK (for example CI-1040 and PD-098059), inhibitors of
25 mTOR (for example Wyeth CCI-779), and inhibitors of PI3K (for example LY294002).


As described above, the combinations with NSAID's are directed to the use of NSAID's which are potent COX-2 inhibiting agents. For purposes of this specification an NSAID is potent if it possess an IC₅₀ for the inhibition of COX-2 of
30 1μM or less as measured by cell or microsomal assays.

The invention also encompasses combinations with NSAID's which are selective COX-2 inhibitors. For purposes of this specification NSAID's which are selective inhibitors of COX-2 are defined as those which possess a specificity for inhibiting COX-2 over COX-1 of at least 100 fold as measured by the ratio of IC₅₀
35 for COX-2 over IC₅₀ for COX-1 evaluated by cell or microsomal assays. Such


compounds include, but are not limited to those disclosed in U.S. Patent 5,474,995, issued December 12, 1995, U.S. Patent 5,861,419, issued January 19, 1999, U.S. Patent 6,001,843, issued December 14, 1999, U.S. Patent 6,020,343, issued February 1, 2000, U.S. Patent 5,409,944, issued April 25, 1995, U.S. Patent 5,436,265, issued 5 July 25, 1995, U.S. Patent 5,536,752, issued July 16, 1996, U.S. Patent 5,550,142, issued August 27, 1996, U.S. Patent 5,604,260, issued February 18, 1997, U.S. 5,698,584, issued December 16, 1997, U.S. Patent 5,710,140, issued January 20, 1998, WO 94/15932, published July 21, 1994, U.S. Patent 5,344,991, issued June 6, 1994, U.S. Patent 5,134,142, issued July 28, 1992, U.S. Patent 5,380,738, issued 10 January 10, 1995, U.S. Patent 5,393,790, issued February 20, 1995, U.S. Patent 5,466,823, issued November 14, 1995, U.S. Patent 5,633,272, issued May 27, 1997, and U.S. Patent 5,932,598, issued August 3, 1999, all of which are hereby incorporated by reference.

15 Inhibitors of COX-2 that are particularly useful in the instant method of treatment are:

3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone; and





5-chloro-3-(4-(methylsulfonyl)phenyl)-2-(2-methyl-5-pyridinyl)pyridine;




20 or a pharmaceutically acceptable salt thereof.

General and specific synthetic procedures for the preparation of the COX-2 inhibitor compounds described above are found in U.S. Patent No. 5,474,995, issued December 12, 1995, U.S. Patent No. 5,861,419, issued January 19, 1999, and U.S. Patent No. 6,001,843, issued December 14, 1999, all of which are herein
5 incorporated by reference.

Compounds that have been described as specific inhibitors of COX-2 and are therefore useful in the present invention include, but are not limited to, the following:



10



or a pharmaceutically acceptable salt thereof.

Compounds which are described as specific inhibitors of COX-2 and are therefore useful in the present invention, and methods of synthesis thereof, can be found in the following patents, pending applications and publications, which are herein incorporated by reference: WO 94/15932, published July 21, 1994, U.S. Patent No. 5,344,991, issued June 6, 1994, U.S. Patent No. 5,134,142, issued July 28, 1992, U.S. Patent No. 5,380,738, issued January 10, 1995, U.S. Patent No. 5,393,790, issued February 20, 1995, U.S. Patent No. 5,466,823, issued November 14, 1995, U.S. Patent No. 5,633,272, issued May 27, 1997, and U.S. Patent No. 5,932,598, issued August 3, 1999.

Compounds which are specific inhibitors of COX-2 and are therefore useful in the present invention, and methods of synthesis thereof, can be found in the following patents, pending applications and publications, which are herein incorporated by reference: U.S. Patent No. 5,474,995, issued December 12, 1995, U.S. Patent No. 5,861,419, issued January 19, 1999, U.S. Patent No. 6,001,843, issued December 14, 1999, U.S. Patent No. 6,020,343, issued February 1, 2000, U.S. Patent No. 5,409,944, issued April 25, 1995, U.S. Patent No. 5,436,265, issued July 25, 1995, U.S. Patent No. 5,536,752, issued July 16, 1996, U.S. Patent No. 5,550,142, issued August 27, 1996, U.S. Patent No. 5,604,260, issued February 18, 1997, U.S. Patent No. 5,698,584, issued December 16, 1997, and U.S. Patent No. 5,710,140, issued January 20, 1998.

Other examples of angiogenesis inhibitors include, but are not limited to, endostatin, ukrain, ranpirnase, IM862, 5-methoxy-4-[2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-1-oxaspiro[2,5]oct-6-yl(chloroacetyl)carbamate, acetyldinanaline, 5-amino-1-[[3,5-dichloro-4-(4-chlorobenzoyl)phenyl]methyl]-1H-1,2,3-triazole-4-carboxamide, CM101, squalamine, combretastatin, RPI4610, NX31838, sulfated mannopentaose phosphate, 7,7-(carbonyl-bis[imino-N-methyl-4,2-pyrrolocarbonylimino[N-methyl-4,2-pyrrole]-carbonylimino]-bis-(1,3-naphthalene disulfonate), and 3-[(2,4-dimethylpyrrol-5-yl)methylene]-2-indolinone (SU5416).

As used above, "integrin blockers" refers to compounds which selectively antagonize, inhibit or counteract binding of a physiological ligand to the $\alpha_v\beta_3$ integrin, to compounds which selectively antagonize, inhibit or counteract binding of a physiological ligand to the $\alpha_v\beta_5$ integrin, to compounds which antagonize, inhibit or counteract binding of a physiological ligand to both the $\alpha_v\beta_3$ integrin and the $\alpha_v\beta_5$ integrin, and to compounds which antagonize, inhibit or counteract the activity of the particular integrin(s) expressed on capillary endothelial

cells. The term also refers to antagonists of the $\alpha_v\beta_6$, $\alpha_v\beta_8$, $\alpha_1\beta_1$, $\alpha_2\beta_1$, $\alpha_5\beta_1$, $\alpha_6\beta_1$ and $\alpha_6\beta_4$ integrins. The term also refers to antagonists of any combination of $\alpha_v\beta_3$, $\alpha_v\beta_5$, $\alpha_v\beta_6$, $\alpha_v\beta_8$, $\alpha_1\beta_1$, $\alpha_2\beta_1$, $\alpha_5\beta_1$, $\alpha_6\beta_1$ and $\alpha_6\beta_4$ integrins.

Some specific examples of tyrosine kinase inhibitors include N-
 5 (trifluoromethylphenyl)-5-methylisoxazol-4-carboxamide, 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]indolin-2-one, 17-(allylamino)-17-demethoxygeldanamycin, 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-[3-(4-morpholinyl)propoxyl]quinazoline, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine, BIBX1382,
 2,3,9,10,11,12-hexahydro-10-(hydroxymethyl)-10-hydroxy-9-methyl-9,12-epoxy-1H-
 10 diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, SH268, genistein, STI571, CEP2563, 4-(3-chlorophenylamino)-5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidinemethane sulfonate, 4-(3-bromo-4-hydroxyphenyl)amino-6,7-dimethoxyquinazoline, 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline, SU6668, STI571A, N-4-chlorophenyl-4-(4-pyridylmethyl)-1-phthalazinamine, and
 15 EMD121974.

Combinations with compounds other than anti-cancer compounds are also encompassed in the instant methods. For example, combinations of the instantly claimed compounds with PPAR- γ (i.e., PPAR-gamma) agonists and PPAR- δ (i.e., PPAR-delta) agonists are useful in the treatment of certain malignancies. PPAR- γ
 20 and PPAR- δ are the nuclear peroxisome proliferator-activated receptors γ and δ . The expression of PPAR- γ on endothelial cells and its involvement in angiogenesis has been reported in the literature (see *J. Cardiovasc. Pharmacol.* 1998; 31:909-913; *J. Biol. Chem.* 1999;274:9116-9121; *Invest. Ophthalmol Vis. Sci.* 2000; 41:2309-2317). More recently, PPAR- γ agonists have been shown to inhibit the angiogenic response
 25 to VEGF in vitro; both troglitazone and rosiglitazone maleate inhibit the development of retinal neovascularization in mice. (*Arch. Ophthalmol.* 2001; 119:709-717). Examples of PPAR- γ agonists and PPAR- γ/α agonists include, but are not limited to, thiazolidinediones (such as DRF2725, CS-011, troglitazone, rosiglitazone, and pioglitazone), fenofibrate, gemfibrozil, clofibrate, GW2570, SB219994, AR-
 30 H039242, JTT-501, MCC-555, GW2331, GW409544, NN2344, KRP297, NP0110, DRF4158, NN622, GI262570, PNU182716, DRF552926, 2-[(5,7-dipropyl-3-trifluoromethyl-1,2-benzisoxazol-6-yl)oxy]-2-methylpropionic acid (disclosed in USSN 09/782,856), and 2(R)-7-(3-(2-chloro-4-(4-fluorophenoxy) phenoxy)propoxy)-2-ethylchromane-2-carboxylic acid (disclosed in USSN 60/235,708 and 60/244,697).

Another embodiment of the instant invention is the use of the presently disclosed compounds in combination with gene therapy for the treatment of cancer. For an overview of genetic strategies to treating cancer see Hall et al (*Am. J. Hum. Genet.* 61:785-789, 1997) and Kufe et al (*Cancer Medicine*, 5th Ed, pp 876-889, BC Decker, Hamilton 2000). Gene therapy can be used to deliver any tumor suppressing gene. Examples of such genes include, but are not limited to, p53, which can be delivered via recombinant virus-mediated gene transfer (see U.S. Patent No. 6,069,134, for example), a uPA/uPAR antagonist ("Adenovirus-Mediated Delivery of a uPA/uPAR Antagonist Suppresses Angiogenesis-Dependent Tumor Growth and Dissemination in Mice," *Gene Therapy*, August 1998;5(8):1105-13), and interferon gamma (*J. Immunol.* 2000;164:217-222).

The compounds of the instant invention may also be administered in combination with an inhibitor of inherent multidrug resistance (MDR), in particular MDR associated with high levels of expression of transporter proteins. Such MDR inhibitors include inhibitors of p-glycoprotein (P-gp), such as LY335979, XR9576, OC144-093, R101922, VX853 and PSC833 (valsopodar).

A compound of the present invention may be employed in conjunction with anti-emetic agents to treat nausea or emesis, including acute, delayed, late-phase, and anticipatory emesis, which may result from the use of a compound of the present invention, alone or with radiation therapy. For the prevention or treatment of emesis, a compound of the present invention may be used in conjunction with other anti-emetic agents, especially neurokinin-1 receptor antagonists, 5HT3 receptor antagonists, such as ondansetron, granisetron, tropisetron, and zatisetron, GABAB receptor agonists, such as baclofen, a corticosteroid such as Decadron (dexamethasone), Kenalog, Aristocort, Nasalide, Preferid, Benecorten or others such as disclosed in U.S. Patent Nos. 2,789,118, 2,990,401, 3,048,581, 3,126,375, 3,929,768, 3,996,359, 3,928,326 and 3,749,712, an antidopaminergic, such as the phenothiazines (for example prochlorperazine, fluphenazine, thioridazine and mesoridazine), metoclopramide or dronabinol. For the treatment or prevention of emesis that may result upon administration of the instant compounds, conjunctive therapy with an anti-emesis agent selected from a neurokinin-1 receptor antagonist, a 5HT3 receptor antagonist and a corticosteroid is preferred.

Neurokinin-1 receptor antagonists of use in conjunction with the compounds of the present invention are fully described, for example, in U.S. Patent Nos. 5,162,339, 5,232,929, 5,242,930, 5,373,003, 5,387,595, 5,459,270, 5,494,926,

In an embodiment, the neurokinin-1 receptor antagonist for use in conjunction with the compounds of the present invention is selected from: 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)morpholine, or a pharmaceutically acceptable salt thereof, which is described in U.S. Patent No. 5,719,147.

35 A compound of the instant invention may also be administered with an agent useful in the treatment of neutropenia. Such a neutropenia treatment agent is,

for example, a hematopoietic growth factor which regulates the production and function of neutrophils such as a human granulocyte colony stimulating factor, (G-CSF). Examples of a G-CSF include filgrastim.

5 A compound of the instant invention may also be administered with an immunologic-enhancing drug, such as levamisole, isoprinosine and Zadaxin.

Thus, the scope of the instant invention encompasses the use of the instantly claimed compounds in combination with a second compound selected from:

- 1) an estrogen receptor modulator,
- 2) an androgen receptor modulator,
- 10 3) retinoid receptor modulator,
- 4) a cytotoxic/cytostatic agent,
- 5) an antiproliferative agent,
- 6) a prenyl-protein transferase inhibitor,
- 7) an HMG-CoA reductase inhibitor,
- 15 8) an HIV protease inhibitor,
- 9) a reverse transcriptase inhibitor,
- 10) an angiogenesis inhibitor,
- 11) PPAR- γ agonists,
- 12) PPAR- δ agonists,
- 20 13) an inhibitor of inherent multidrug resistance,
- 14) an anti-emetic agent,
- 15) an agent useful in the treatment of anemia,
- 16) an agent useful in the treatment of neutropenia,
- 17) an immunologic-enhancing drug,
- 25 18) an inhibitor of cell proliferation and survival signaling, and
- 19) an agent that interferes with a cell cycle checkpoint.

In an embodiment, the angiogenesis inhibitor to be used as the second compound is selected from a tyrosine kinase inhibitor, an inhibitor of epidermal-derived growth factor, an inhibitor of fibroblast-derived growth factor, an inhibitor of platelet derived growth factor, an MMP (matrix metalloprotease) inhibitor, an integrin
30 blocker, interferon- α , interleukin-12, pentosan polysulfate, a cyclooxygenase inhibitor, carboxyamidotriazole, combretastatin A-4, squalamine, 6-O-chloroacetyl-carbonyl)-fumagillol, thalidomide, angiostatin, troponin-1, or an antibody to VEGF. In an embodiment, the estrogen receptor modulator is tamoxifen or raloxifene.

Also included in the scope of the claims is a method of treating cancer that comprises administering a therapeutically effective amount of a compound of Formula A in combination with radiation therapy and/or in combination with a second compound selected from:

- 5 1) an estrogen receptor modulator,
- 2) an androgen receptor modulator,
- 3) a retinoid receptor modulator,
- 4) a cytotoxic/cytostatic agent,
- 5) an antiproliferative agent,
- 10 6) a prenyl-protein transferase inhibitor,
- 7) an HMG-CoA reductase inhibitor,
- 8) an HIV protease inhibitor,
- 9) a reverse transcriptase inhibitor,
- 10) an angiogenesis inhibitor,
- 15 11) PPAR- γ agonists,
- 12) PPAR- δ agonists,
- 13) an inhibitor of inherent multidrug resistance,
- 14) an anti-emetic agent,
- 15) an agent useful in the treatment of anemia,
- 20 16) an agent useful in the treatment of neutropenia,
- 17) an immunologic-enhancing drug,
- 18) an inhibitor of cell proliferation and survival signaling, and
- 19) an agent that interferes with a cell cycle checkpoint.

And yet another embodiment of the invention is a method of treating
25 cancer that comprises administering a therapeutically effective amount of a compound of Formula A in combination with paclitaxel or trastuzumab.

The invention further encompasses a method of treating or preventing cancer that comprises administering a therapeutically effective amount of a compound of Formula I in combination with a COX-2 inhibitor.

30 The instant invention also includes a pharmaceutical composition useful for treating or preventing cancer that comprises a therapeutically effective amount of a compound of Formula A and a second compound selected from:

- 1) an estrogen receptor modulator,
- 2) an androgen receptor modulator,
- 35 3) a retinoid receptor modulator,

- 4) a cytotoxic/cytostatic agent,
- 5) an antiproliferative agent,
- 6) a prenyl-protein transferase inhibitor,
- 7) an HMG-CoA reductase inhibitor,
- 5 8) an HIV protease inhibitor,
- 9) a reverse transcriptase inhibitor,
- 10) an angiogenesis inhibitor,
- 11) a PPAR- γ agonist,
- 12) a PPAR- δ agonist,
- 10 13) an inhibitor of cell proliferation and survival signaling, and
- 14) an agent that interferes with a cell cycle checkpoint.

When a composition according to this invention is administered into a human subject, the daily dosage will normally be determined by the prescribing physician with the dosage generally varying according to the age, weight, and
 15 response of the individual patient, as well as the severity of the patient's symptoms.

In one embodiment, a suitable amount of an inhibitor of Akt is administered to a mammal undergoing treatment for cancer. Administration occurs in an amount of inhibitor of between about 0.1 mg/kg of body weight to about 60 mg/kg of body weight per day, preferably of between 0.5 mg/kg of body weight to about 40
 20 mg/kg of body weight per day. Another therapeutic dosage that comprises the instant composition includes from about 0.01 mg to about 1000 mg of inhibitor of Akt. In another embodiment, the dosage comprises from about 1 mg to about 1000 mg of inhibitor of Akt.

All patents, publications and pending patent applications identified are
 25 hereby incorporated by reference.

Abbreviations used in the description of the chemistry and in the Examples that follow are:

| | |
|-------------------|---------------------------------------|
| AEBSF | p-aminoethylbenzenesulfonyl fluoride; |
| 30 BSA | bovine serum albumin; |
| CuI | copper iodide; |
| CuSO ₄ | copper sulfate; |
| DMSO | dimethyl sulfoxide; |
| DTT | dithiothreitol; |
| 35 EDTA | ethylene-diamine-tetra-acetic acid; |

| | | |
|----|---------------------------------|---|
| | EGTA | ethylene-glycol-tetra-acetic acid; |
| | EtOAc | ethyl acetate; |
| | EtOH | ethanol; |
| | HOAc | acetic acid; |
| 5 | HPLC | high-performance liquid chromatography; |
| | LCMS | liquid chromatograph-mass spectrometer; |
| | MeOH | methanol; |
| | NaHCO ₃ | sodium bicarbonate; |
| | Na ₂ SO ₄ | sodium sulfate; |
| 10 | NH ₄ OAc | ammonium acetate; |
| | NBS | N-bromosuccinamide; |
| | NMR | nuclear magnetic resonance; |
| | PBS | phosphate buffered saline; |
| | PCR | polymerase chain reaction; |
| 15 | PS-DIEA | polystyrene diisopropylethylamine; |
| | THF | tetrahydrofuran; and |
| | TFA | trifluoroacetic acid. |

20 The compounds of this invention may be prepared by employing reactions as shown in the following Reaction Schemes, in addition to other standard manipulations that are known in the literature or exemplified in the experimental procedures. The illustrative Reaction Schemes below, therefore, are not limited by the compounds listed or by any particular substituents employed for illustrative purposes. Substituent numbering as shown in the Reaction Schemes does not necessarily
25 correlate to that used in the claims and often, for clarity, a single substituent is shown attached to the compound where multiple substituents are allowed under the definitions of Formula A hereinabove.

Reactions used to generate the compounds of this invention are prepared by employing reactions as shown in the Reaction Schemes I-IV, in addition
30 to other standard manipulations such as ester hydrolysis, cleavage of protecting groups, etc., as may be known in the literature or exemplified in the experimental procedures.


These reactions may be employed in a linear sequence to provide the compounds of the invention or they may be used to synthesize fragments which are
35 subsequently joined by the alkylation reactions described in the Reaction Schemes.

SYNOPSIS OF REACTION SCHEMES:

The requisite intermediates are in some cases commercially available, or can be prepared according to literature procedures. As illustrated in Reaction Scheme I, a suitably substituted phenylacetylide may be reacted with copper iodide to form the corresponding copper acetylide I-1 (see for example, Sonogashira, K.; Toda, Y.; Hagihara, N. *Tetrahedron Lett.* 1975, 4467). Intermediate I-1 may then react with a suitably substituted electrophilic phenyl moiety to provide the asymmetrically substituted diphenyl acetylene I-2. Reaction with NBS followed by hydrolysis provides the substituted benzil I-3 (see for example, Yussybov, M.S.; Filimonov, V.D.; *Synthesis* 1991, 2:131). A variety of substituted and unsubstituted benzils may also be obtained commercially.


Reaction Scheme II illustrates the preparation of the compounds of the instant invention, starting with a suitably substituted bromomethylbenzil II-1. This intermediate can be reacted with a suitable amine to provide intermediate II-2.

Reaction Scheme III, illustrates the synthesis of heterocyclic triazines by reacting a three component condensation with the appropriate benzil III-1 (note





represents numerous cyclic and non-cyclic substituents, including, but not limited to substituted-aryl and -heterocyclyl groups, that are easily synthesized by one of ordinary skill in the art), ammonium acetate and with a substituted carbohydrazide III-2. The appropriately substituted carbohydrazides are easily synthesized by those of ordinary skill in the art and include, but are not limited to, numerous substituted-cyclic and -non-cyclic moieties.


Reaction Scheme IV illustrates the synthesis of heterocyclic triazines utilizing various alkylating agents (well known to those of ordinary skill in the art, for example (trimethylsilyl)diazomethane) to produce numerous substituted-cyclic and -non-cyclic R¹ groups (as shown in IV-3A and IV-3B).

Reaction Scheme I

5

Reaction Scheme II


Reaction Scheme III

Reaction Scheme IV

EXAMPLES


Examples provided are intended to assist in a further understanding of the invention. Particular materials employed, species and conditions are intended to be further illustrative of the invention and not limitative of the reasonable scope thereof. The reagents utilized in synthesizing the compounds depicted in the following Tables are either commercially available or are readily prepared by one of ordinary skill in the art.

SCHEME 1



To a 5 mL Smith Reaction vial with a stir bar was placed benzil, (1-1), (44 mg, 0.1 mol), ammonium acetate (39 mg, 1 mmol, 10 equiv.); 1,3-thiazole-5-carbohydrazide, (1-2), (13 mg, 0.1 mol) and 1 mL of glacial acetic acid. The reaction vessel was heated in a SmithSynthesizer™ for 5 minutes at 180°C. After 5 minutes, the reaction vessel was rapidly cooled to 40°C by the unit. Concentration of the resulting reaction in a Genevac HTII-12 provided a bright yellow gum. LCMS analysis indicated a 2.5:1 mixture of (1-3:1-4). The gum was subsequently dissolved in 1 mL of DMSO and purified by mass-triggered HPLC. After concentration and drying, the title compound, (1-3), was delivered as a bright yellow solid, free from any impurity of (1-4). ¹H NMR (300 MHz, CDCl₃): 9.59 (s, 1H), 9.04 (s, 1H), 8.93 (s, 1H), 7.27 (m, 1H), 7.66 (m, 1H), 7.52 (m, 3H), 7.39 (m, 3H), 7.06 (s, 4H), 4.31 (s, 2H), 3.73 (m, 1H), 2.91 (m, 4H), 1.97 (m, 4H); HRMS calc'd for C₃₁H₂₇N₇OS (M+H), 546.2067; found 546.2061.

SCHEME 2



- 5 1-{1-[4-(3-oxo-6-phenyl-2,3-dihydro-1,2,4-triazin-5-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one (2-2) and 1-{1-[4-(3-oxo-5-phenyl-2,3-dihydro-1,2,4-triazin-6-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one (2-3)

To a solution of 1-(4-{[4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl]methyl}phenyl)-2-phenylethane-1,2-dione (1-1) (0.129 g, 0.29 mmol) in 85% aq. HOAc (2 mL) was added semicarbazide hydrochloride (2-1) (0.033 g, 0.29 mmol). The reaction was heated to 125°C for 2.5hr then cooled to RT. The reaction was concentrated in vacuo to afford a yellow oil. The oil was dissolved in water (50 mL) and sat. aq. NaHCO₃ was used to adjust from pH 4 to pH 6. The yellow precipitate that formed was dissolved in EtOAc and the layers were separated.

15 The aq. layer was further extracted with EtOAc (2 x 50 mL). The combined organics were dried over Na₂SO₄, filtered, and concentrated in vacuo to afford a yellow oil.

The oil was purified by flash column chromatography (gradient, 5-10% MeOH/CH₂Cl₂). The fractions containing desired product were combined and concentrated to afford a light yellow solid. The solid was a mixture (1:1.5 ratio) of the title compounds as determined by ¹H NMR (CDCl₃). [M+H]⁺ = 479.2183.

5

1-{1-[4-(2-methyl-3-oxo-6-phenyl-2,3-dihydro-1,2,4-triazin-5-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one (2-4) and 1-{1-[4-(2-methyl-3-oxo-5-phenyl-2,3-dihydro-1,2,4-triazin-6-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one (2-5)

10

To a solution of 1-{1-[4-(3-oxo-6-phenyl-2,3-dihydro-1,2,4-triazin-5-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one (2-2) and 1-{1-[4-(3-oxo-5-phenyl-2,3-dihydro-1,2,4-triazin-6-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one (2-3) (1:1.5 mixture of unassigned regioisomers, 0.034 g, 0.07 mmol) in 2:1 CH₂Cl₂:MeOH (1.5 mL) was added (trimethylsilyl)diazomethane (2M solution in hexanes, 0.036 mL, 0.07 mmol). The reaction was stirred at ambient temperature for 1.5hr. HOAc was added drop-wise until bubbling ceased. The reaction was concentrated in vacuo to afford a yellow oil. The oil was purified by reverse phase chromatography (gradient, 5-100% CH₃CN/H₂O + 0.1% TFA). The fractions containing the separated regioisomers were each combined and concentrated to afford the TFA salts of the title compounds. 1-{1-[4-(2-methyl-3-oxo-6-phenyl-2,3-dihydro-1,2,4-triazin-5-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one (2-4): ¹H NMR (CDCl₃) δ 8.34 (bs, 1H), 7.56 (d, 2H, J = 8.06 Hz), 7.44-7.27 (m, 7H), 7.14-7.05 (m, 4H), 4.68 (m, 1H), 4.26 (s, 2H), 3.96 (s, 3H), 3.72 (d, 2H, J = 11.97 Hz), 2.94-2.81 (m, 4H), 1.99 (m, 2H). [M+H]⁺ = 493.2352. 1-{1-[4-(2-methyl-3-oxo-5-phenyl-2,3-dihydro-1,2,4-triazin-6-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one (2-5): ¹H NMR (CDCl₃) δ 8.06 (bs, 1H), 7.48-7.40 (m, 8H), 7.33-7.30 (m, 2H), 7.14-7.05 (m, 3H), 4.69 (m, 1H), 4.26 (s, 2H), 3.95 (s, 3H), 3.73 (d, 2H, J = 11.96 Hz), 2.96-2.91 (m, 2H), 2.85-2.81 (m, 2H), 2.00 (d, 2H, J = 13.43 Hz). [M+H]⁺ = 493.2318.





30

Compounds in Table 1 were synthesized as shown in Scheme 1, but substituting the appropriately substituted carbonylhydrazide for compound (1-2) in Scheme 1: Unless otherwise stated, the TFA salt of the compound shown was isolated by Mass Guided HPLC purification.

Even though only one regioisomer is depicted in Table 1, both isomers were synthesized (as demonstrated in Scheme 1).






Table 1

5

| Compound | Nomenclature | MS M+1 |
|---|--|-----------|
|  | 1-(1-{4-[3-(1,3-oxazol-2-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one | 530.6 |
|  | 1-{1-[4-(6-phenyl-3-pyrimidin-2-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one | 541.6 |
|  | 1-(1-{4-[3-(1H-imidazol-2-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one | 529.6 |
|  | 1-(1-{4-[3-(1-methyl-1H-pyrazol-5-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one | 543.6 |

- 60 -

- 61 -

| | | |
|---|--|-------|
|  | 1-(1-{4-[(6-phenyl-3-pyridin-4-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one | 540.6 |
|  | 1-(1-{4-[(3-(morpholin-4-ylmethyl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one | 562.6 |
|  | 1-(1-{4-[(6-phenyl-3-(1,3-thiazol-2-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one | 546.6 |
|  | 1-(1-{4-[(6-phenyl-3-(1,3-thiazol-5-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one | 546.6 |
|  | 1-(1-{4-[(6-phenyl-3-(1H-1,2,3-triazol-5-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one | 530.6 |

| | | |
|--|--|-------|
| | 1-(1-{4-[6-phenyl-3-(1,3-thiazol-4-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one | 546.6 |
| | 1-(1-{4-[3-(1,1'-biphenyl-4-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one | 615.7 |

The compound in Table 2 was synthesized as shown in Scheme 2, but substituting the appropriately substituted semicarbazide for compound (2-1) in Scheme 2: Unless otherwise stated, the TFA salt of the compound shown was isolated by Mass Guided HPLC purification.

Even though only one regioisomer is depicted in Table 2, both isomers were synthesized (as demonstrated in Scheme 2).

Table 2

10

| Compound | Nomenclature | MS M+1 |
|----------|--|-----------|
| | 1-(1-{4-[3-(methylthio)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one | 509.2 |

Cloning of the human Akt isoforms and Δ PH-Akt1

Human Akt1 gene was amplified by PCR (Clontech) out of a human spleen cDNA (Clontech) using the 5' primer:
20 5'CGCGAATTCAGATCTACCATGAGCGACGTGGCTATTGTG 3' (SEQ.ID.NO.: 3), and the 3' primer: 5'CGCTCTAGAGGATCCTCAGGCCGTGCTGCTGGC3' (SEQ.ID.NO.: 4). The 5' primer included an EcoRI and BglII site. The 3' primer included an XbaI and BamHI site for cloning purposes. The resultant PCR product was subcloned into pGEM3Z (Promega) as an EcoRI / Xba I fragment. For
25 expression / purification purposes, a middle T tag was added to the 5' end of the full length Akt1 gene using the PCR primer: 5'GTACGATGCTGAACGATATCTTCG 3' (SEQ.ID.NO.: 5). The resulting PCR product encompassed a 5' KpnI site and a 3' BamHI site which were used to subclone the fragment in frame with a biotin tag containing insect cell expression vector, pS2neo.

- 64 -

(SEQ.ID.NO.: 6), and

5' CCCCTCCATCTCTTCAGCCCCGTCGCTTTCCATCGGCATG

TATTC 3' (SEQ.ID.NO.: 7)) which encompassed the deletion and 5' and 3' flanking primers which encompassed the KpnI site and middle T tag on the 5' end. The final

- 5 PCR product was digested with KpnI and SmaI and ligated into the pS2neo full length Akt1 KpnI / Sma I cut vector, effectively replacing the 5' end of the clone with the deleted version.

Human Akt3 gene was amplified by PCR of adult brain cDNA (Clontech) using the amino terminal oligo primer:

- 10 5' GAATTCAGATCTACCATGAGCGATGTTACCATTGTG 3' (SEQ.ID.NO.: 8); and the carboxy terminal oligo primer :

5' TCTAGATCTTATTCTCGTCCACTTGCAGAG 3' (SEQ.ID.NO.: 9).

These primers included a 5' EcoRI / BglII site and a 3' XbaI / BglII site for cloning purposes. The resultant PCR product was cloned into the EcoRI and XbaI sites of

- 15 pGEM4Z (Promega). For expression / purification purposes, a middle T tag was added to the 5' end of the full length Akt3 clone using the PCR primer: 5' GGTACCATGGAATACATGCCGATGGAAAGCGATGTTACCATTGTGAAG 3' (SEQ.ID.NO.: 10). The resultant PCR product encompassed a 5' KpnI site which allowed in frame cloning with the biotin tag containing insect cell expression vector, 20 pS2neo.

Human Akt2 gene was amplified by PCR from human thymus cDNA (Clontech) using the amino terminal oligo primer:

5' AAGCTTAGATCTACCATGAATGAGGTGTCTGTC 3' (SEQ.ID.NO.: 11); and the carboxy terminal oligo primer: 5'

- 25 GAATTCGGATCCTCACTCGCGGATGCTGGC 3' (SEQ.ID.NO.: 12). These primers included a 5' HindIII / BglII site and a 3' EcoRI / BamHI site for cloning purposes. The resultant PCR product was subcloned into the HindIII / EcoRI sites of pGem3Z (Promega). For expression / purification purposes, a middle T tag was added to the 5' end of the full length Akt2 using the PCR primer: 5' 30 GGTACCATGGAATACATGCCGATGGAAAATGAGGTGTCTGTGCATCAAAG 3' (SEQ.ID.NO.: 13). The resultant PCR product was subcloned into the pS2neo vector as described above.

EXAMPLE 2

Expression of human Akt isoforms and Δ PH-Akt1

The DNA containing the cloned Akt1, Akt2, Akt3 and Δ PH-Akt1
5 genes in the pS2neo expression vector was purified and used to transfect *Drosophila*
S2 cells (ATCC) by the calcium phosphate method. Pools of antibiotic (G418, 500
 μ g/ml) resistant cells were selected. Cells were expanded to a 1.0 L volume ($\sim 7.0 \times$
 10^6 / ml), biotin and CuSO_4 were added to a final concentration of 50 μ M and 50 mM
respectively. Cells were grown for 72 h at 27°C and harvested by centrifugation. The
10 cell paste was frozen at -70°C until needed.

EXAMPLE 3

Purification of human Akt isoforms and Δ PH-Akt1

15 Cell paste from one liter of S2 cells, described in Example 2, was lysed
by sonication with 50 mls 1% CHAPS in buffer A: (50 mM Tris pH 7.4, 1 mM
EDTA, 1 mM EGTA, 0.2 mM AEBSF, 10 μ g/ml benzamidine, 5 μ g/ml of leupeptin,
aprotinin and pepstatin each, 10% glycerol and 1 mM DTT). The soluble fraction
was purified on a Protein G Sepharose fast flow (Pharmacia) column loaded with
20 9mg/ml anti-middle T monoclonal antibody and eluted with 75 μ M EYMPME
(SEQ.ID.NO.: 14) peptide in buffer A containing 25% glycerol. Akt containing
fractions were pooled and the protein purity evaluated by SDS-PAGE. The purified
protein was quantitated using a standard Bradford protocol. Purified protein was
flash frozen on liquid nitrogen and stored at -70°C.

25 Akt and Akt pleckstrin homology domain deletions purified from S2
cells required activation. Akt and Akt pleckstrin homology domain deletions was
activated (Alessi et al. *Current Biology* 7:261-269) in a reaction containing 10 nM
PDK1 (Upstate Biotechnology, Inc.), lipid vesicles (10 μ M phosphatidylinositol-
3,4,5-trisphosphate – Metreya, Inc, 100 μ M phosphatidylcholine and 100 μ M
30 phosphatidylserine – Avanti Polar lipids, Inc.) and activation buffer (50 mM Tris
pH7.4, 1.0 mM DTT, 0.1 mM EGTA, 1.0 μ M Microcystin-LR, 0.1 mM ATP, 10 mM
 MgCl_2 , 333 μ g/ml BSA and 0.1mM EDTA). The reaction was incubated at 22°C for
4 hours. Aliquots were flash frozen in liquid nitrogen.

300PV

H. 10X Assay Buffer: 500 mM HEPES, pH 7.5, 1% PEG, mM EDTA, 1 mM EGTA, 1% BSA, 20 mM β -Glycerol phosphate.

I. Quench Buffer: 50 mM HEPES pH 7.3, 16.6 mM EDTA, 0.1% BSA,
5 0.1% Triton X-100, 0.17 nM Lance labeled monoclonal antibody clone # 27, 0.0067 mg/ml SA-APC

J. ATP/MgCl₂ working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 125 mM KCl, 5% Glycerol, 25 mM MgCl₂, 375 μ M ATP
10

K. Enzyme working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% Glycerol, active Akt. The final enzyme concentrations were selected so that the assay was in a linear response range.

15 L. Peptide working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% Glycerol, 2 μ M GSK3 biotinylated peptide # 3928

The reaction is assembled by adding 16 μ L of the ATP/MgCl₂ working solution to the appropriate wells of a 96-well microtiter plate. Inhibitor or vehicle (1.0 μ l) is added followed by 10 μ l of peptide working solution. The reaction is started by adding 13 μ l of the enzyme working solution and mixing. The reaction is allowed to proceed for 50 min and then stopped by the addition of 60 μ l HTRF quench buffer. The stopped reactions were incubated at room temperature for at least 30 min and then read on the Discovery instrument.

25

PKA assay:

Each individual PKA assay consists of the following components:

30

A. 5X PKA assay buffer (200 mM Tris pH7.5, 100 mM MgCl₂, 5mM β -mercaptoethanol, 0.5 mM EDTA)

B. 50 μ M stock of Kemptide (Sigma) diluted in water

35

EXAMPLE 4

Akt Kinase Assays

Activated Akt isoforms and pleckstrin homology domain deletion constructs were assayed utilizing a GSK-derived biotinylated peptide substrate. The extent of peptide phosphorylation was determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate(Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide. When the Lance and APC are in proximity (i.e. bound to the same phosphopeptide molecule), a non-radiative energy transfer takes place from the Lance to the APC, followed by emission of light from APC at 665 nm.

Materials required for the assay:

- 15 A. Activated Akt isozyme or pleckstrin homology domain deleted construct
- B. Akt peptide substrate: GSK3 α (S21) Peptide no.3928 biotin-GGRARTSSFAEPG (SEQ.ID.NO.:15), Macromolecular Resources.
- 20 C. Lance labeled anti-phospho GSK3 α monoclonal antibody (Cell Signaling Technology, clone # 27).
- 25 D. SA-APC (Prozyme catalog no. PJ25S lot no. 896067).
- E. Microfluor[®]B U Bottom Microtiter Plates (Dynex Technologies, Catalog no. 7205).
- 30 F. Discovery[®] HTRF Microplate Analyzer, Packard Instrument Company.
- G. 100 X Protease Inhibitor Cocktail (PIC): 1 mg/ml benzamidine, 0.5 mg/ml pepstatin, 0.5 mg/ml leupeptin, 0.5 mg/ml aprotinin.

35

C. ^{33}P -ATP prepared by diluting 1.0 μl ^{33}P -ATP [10 mCi/ml] into 200 μl of a 50 μM stock of unlabeled ATP

D. 10 μl of a 70 nM stock of PKA catalytic subunit (UBI catalog # 14-114) diluted in 0.5 mg/ml BSA

E. PKA/Kemptide working solution: equal volumes of 5X PKA assay buffer, Kemptide solution and PKA catalytic subunit.

10 The reaction is assembled in a 96 deep-well assay plate. The inhibitor or vehicle (10 μl) is added to 10 μl of the ^{33}P -ATP solution. The reaction is initiated by adding 30 μl of the PKA/Kemptide working solution to each well. The reactions were mixed and incubated at room temperature for 20 min. The reactions were stopped by adding 50 μl of 100 mM EDTA and 100 mM sodium pyrophosphate and
15 mixing.

The enzyme reaction product (phosphorylated Kemptide) was collected on p81 phosphocellulose 96 well filter plates (Millipore). To prepare the plate, each well of a p81 filter plate was filled with 75 mM phosphoric acid. The wells were emptied through the filter by applying a vacuum to the bottom of the plate.
20 Phosphoric acid (75 mM, 170 μl) was added to each well. A 30 μl aliquot from each stopped PKA reaction was added to corresponding wells on the filter plate containing the phosphoric acid. The peptide was trapped on the filter following the application of a vacuum and the filters were washed 5 times with 75 mM phosphoric acid. After the final wash, the filters were allowed to air dry. Scintillation fluid (30 μl) was added to
25 each well and the filters counted on a TopCount (Packard).

PKC assay:

Each PKC assay consists of the following components:

30

A. 10X PKC co-activation buffer: 2.5 mM EGTA, 4mM CaCl_2

B. 5X PKC activation buffer: 1.6 mg/ml phosphatidylserine, 0.16 mg/ml diacylglycerol, 100 mM Tris pH 7.5, 50 mM MgCl_2 , 5 mM β -mercaptoethanol

300PV

C. ^{33}P -ATP prepared by diluting 1.0 μl ^{33}P -ATP [10 mCi/ml] into 100 μl of a 100 μM stock of unlabeled ATP

5 D. Myelin basic protein (350 $\mu\text{g/ml}$, UBI) diluted in water

E. PKC (50 ng/ml, UBI catalog # 14-115) diluted into 0.5 mg/ml BSA

10 F. PKC/Myelin Basic Protein working solution: Prepared by mixing 5 volumes each of PKC co-activation buffer and Myelin Basic protein with 10 volumes each of PKC activation buffer and PKC.

The assays were assembled in 96 deep-well assay plates. Inhibitor or vehicle (10 μl) was added to 5.0 μl of ^{33}P -ATP. Reactions were initiated with the addition of the PKC/Myelin Basic Protein working solution and mixing. Reactions were incubated at 30°C for 20 min. The reactions were stopped by adding 50 μl of 100 mM EDTA and 100 mM sodium pyrophosphate and mixing. Phosphorylated Myelin Basic Protein was collected on PVDF membranes in 96 well filter plates and quantitated by scintillation counting.

20 Specific compounds of the instant invention were tested in the assay described above and were found to have IC_{50} of $\leq 50 \mu\text{M}$ against one or more of Akt1, Akt2 and Akt3.

EXAMPLE 5

25

Cell based Assays to Determine Inhibition of Akt

Cells (for example LnCaP or a PTEN^(-/-) tumor cell line with activated Akt) were plated in 100 mM dishes. When the cells were approximately 70 to 80% confluent, the cells were refed with 5 mls of fresh media and the test compound added in solution. Controls included untreated cells, vehicle treated cells and cells treated with either LY294002 (Sigma) or wortmanin (Sigma) at 20 μM or 200 nM, respectively. The cells were incubated for 2, 4 or 6 hrs and the media removed. The cells were washed with PBS, scraped and transferred to a centrifuge tube. They were pelleted and washed again with PBS. Finally, the cell pellet was resuspended in lysis buffer (20 mM Tris pH8, 140 mM NaCl, 2 mM EDTA, 1% Triton, 1 mM Na

35

Pyrophosphate, 10 mM β -Glycerol Phosphate, 10 mM NaF, 0.5 mM NaVO₄, 1 μ M Microsystine, and 1x Protease Inhibitor Cocktail), placed on ice for 15 minutes and gently vortexed to lyse the cells. The lysate was spun in a Beckman tabletop ultra centrifuge at 100,000 x g at 4°C for 20 min. The supernatant protein was quantitated
5 by a standard Bradford protocol (BioRad) and stored at -70° C until needed.

Proteins were immunoprecipitated (IP) from cleared lysates as follows:
For Akt1, lysates are mixed with Santa Cruz sc-7126 (D-17) in NETN (100 mM NaCl, 20 mM Tris pH 8.0, 1 mM EDTA, 0.5% NP-40) and Protein A/G Agarose (Santa Cruz sc-2003) was added. For Akt2, lysates were mixed in NETN with anti-
10 Akt-2 agarose (Upstate Biotechnology #16-174) and for Akt3, lysates were mixed in NETN with anti-Akt3 agarose (Upstate Biotechnology #16-175). The IPs were incubated overnight at 4° C, washed and separated by SDS-PAGE.

Western blots were used to analyze total Akt, pThr308 Akt1, pSer473 Akt1, and corresponding phosphorylation sites on Akt2 and Akt3, and downstream
15 targets of Akt using specific antibodies (Cell Signaling Technology): Anti-Total Akt (cat. no. 9272), Anti-Phospho Akt Serine 473 (cat. no. 9271), and Anti-Phospho Akt Threonine 308 (cat. no. 9275). After incubating with the appropriate primary antibody diluted in PBS + 0.5% non-fat dry milk (NFDm) at 4 °C overnight, blots were washed, incubated with Horseradish peroxidase (HRP)-tagged secondary
20 antibody in PBS + 0.5% NFDm for 1 hour at room temperature. Proteins were detected with ECL Reagents (Amersham/Pharmacia Biotech RPN2134).

EXAMPLE 6

25 Heregulin Stimulated Akt Activation

MCF7 cells (a human breast cancer line that is PTEN^{+/+}) were plated at 1x10⁶ cells per 100 mM plate. When the cells were 70 – 80% confluent, they were refed with 5 ml of serum free media and incubated overnight. The following morning, compound was added and the cells were incubated for 1 – 2 hrs, after which
30 time heregulin was added (to induce the activation of Akt) for 30 minutes and the cells were analyzed as described above.

EXAMPLE 7

Inhibition Of Tumor Growth


5 In vivo efficacy of an inhibitor of the growth of cancer cells may be confirmed by several protocols well known in the art.

Human tumor cell lines which exhibit a deregulation of the PI3K pathway (such as LnCaP, PC3, C33a, OVCAR-3, MDA-MB-468 or the like) are injected subcutaneously into the left flank of 6-10 week old female nude mice (Harlan) on day 0. The mice are randomly assigned to a vehicle, compound or
10 combination treatment group. Daily subcutaneous administration begins on day 1 and continues for the duration of the experiment. Alternatively, the inhibitor test compound may be administered by a continuous infusion pump. Compound, compound combination or vehicle is delivered in a total volume of 0.2 ml. Tumors are excised and weighed when all of the vehicle-treated animals exhibited lesions of
15 0.5 - 1.0 cm in diameter, typically 4 to 5.5 weeks after the cells were injected. The average weight of the tumors in each treatment group for each cell line is calculated.

20

WHAT IS CLAIMED IS:

1. A compound of the Formula A:



5 wherein:

W=Y is selected from CR¹=N, N=CR¹, $\overset{\text{O}}{\parallel}\text{C}-\text{NR}^{1'}$ or $\text{R}^{1'}-\text{N}-\overset{\text{O}}{\parallel}\text{C}$;

```

-   a is 0 or 1;
10  b is 0 or 1;
    m is 0, 1 or 2;
    p is 0, 1 or 2;
    q is 0, 1, 2 or 3;
    r is 0 or 1;
15  s is 0 or 1;
    t is 2, 3, 4, 5 or 6;

```

Q is selected from: H, -NR⁶R⁷, aryl and heterocyclyl, said aryl and heterocyclyl which is optionally substituted with one to three R²;

20

R¹ is independently selected from:

- 25
- 1) H,
 - 2) (C=O)_aO_bC₁-C₁₀ alkyl,
 - 3) (C=O)_aO_baryl,
 - 4) C₂-C₁₀ alkenyl,

- 5) C₂-C₁₀ alkynyl,
 6) (C=O)_aO_b heterocyclyl,
 7) (C=O)_aO_bC₃-C₈ cycloalkyl,
 8) CO₂H,
 5 9) halo,
 10) CN,
 11) OH,
 12) O_bC₁-C₆ perfluoroalkyl,
 13) O_a(C=O)_bNR⁶R⁷,
 10 14) NR^c(C=O)NR⁶R⁷,
 15) S(O)_mR^a,
 16) S(O)₂NR⁶R⁷,
 17) NR^cS(O)_mR^a,
 18) oxo,
 15 19) CHO,
 20) NO₂,
 21) NR^c(C=O)O_bR^a,
 22) O(C=O)O_bC₁-C₁₀ alkyl,
 23) O(C=O)O_bC₃-C₈ cycloalkyl,
 20 24) O(C=O)O_baryl,
 25) O(C=O)O_b-heterocycle, and
 26) O_a-P=O(OH)₂,

said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one or more substituents selected from R^Z;

25

R^{1'} is independently selected from:

- 1) H,
 2) (C=O)_aO_bC₁-C₁₀ alkyl,
 3) (C=O)_aO_baryl,
 30 4) C₂-C₁₀ alkenyl,
 5) C₂-C₁₀ alkynyl,
 6) (C=O)_aO_b heterocyclyl,
 7) (C=O)_aO_bC₃-C₈ cycloalkyl,
 8) CO₂H,

- 5
- 9) halo,
 10) CN,
 11) OH,
 12) $O_bC_1-C_6$ perfluoroalkyl,
 13) $O_a(C=O)_bNR^6R^7$,
 14) $S(O)_mR^a$,
 15) $S(O)_2NR^6R^7$,
 16) oxo,
 17) CHO,
 10 18) $O(C=O)O_bC_1-C_{10}$ alkyl,
 19) $O(C=O)O_bC_3-C_8$ cycloalkyl,
 20) $O(C=O)O_b$ aryl,
 21) $O(C=O)O_b$ -heterocycle, and
 22) $O_a-P=O(OH)_2$.
- 15 said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one or more substituents selected from R^Z ;

R^2 is independently selected from:

- 20 1) $(C=O)_aO_bC_1-C_{10}$ alkyl,
 2) $(C=O)_aO_b$ aryl,
 3) C_2-C_{10} alkenyl,
 4) C_2-C_{10} alkynyl,
 5) $(C=O)_aO_b$ heterocyclyl,
 6) $(C=O)_aO_bC_3-C_8$ cycloalkyl,
 25 7) CO_2H ,
 8) halo,
 9) CN,
 10) OH,
 11) $O_bC_1-C_6$ perfluoroalkyl,
 30 12) $O_a(C=O)_bNR^6R^7$,
 13) $NR^c(C=O)NR^6R^7$,
 14) $S(O)_mR^a$,
 15) $S(O)_2NR^6R^7$,
 16) $NR^cS(O)_mR^a$,
 35 17) CHO,

- 5
- 18) NO_2 ,
 - 19) $\text{NR}^c(\text{C}=\text{O})\text{O}_b\text{R}^a$,
 - 20) $\text{O}(\text{C}=\text{O})\text{O}_b\text{C}_1\text{-C}_{10}$ alkyl,
 - 21) $\text{O}(\text{C}=\text{O})\text{O}_b\text{C}_3\text{-C}_8$ cycloalkyl,
 - 22) $\text{O}(\text{C}=\text{O})\text{O}_b\text{aryl}$,
 - 23) $\text{O}(\text{C}=\text{O})\text{O}_b\text{-heterocycle}$, and
 - 24) $\text{O}_a\text{-P}=\text{O}(\text{OH})_2$.

said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one, two or three substituents selected from R^z ;

10

R^3 and R^4 are independently selected from: H, $\text{C}_1\text{-C}_6$ -alkyl and $\text{C}_1\text{-C}_6$ -perfluoroalkyl, or

- 15 R^3 and R^4 are combined to form $-(\text{CH}_2)_t-$ wherein one of the carbon atoms is optionally replaced by a moiety selected from O, $\text{S}(\text{O})_m$, $-\text{N}(\text{R}^b)\text{C}(\text{O})-$, and $-\text{N}(\text{COR}^a)-$;

R^5 is independently selected from:

- 20
- 1) H,
 - 2) $(\text{C}=\text{O})_a\text{O}_b\text{C}_1\text{-C}_{10}$ alkyl,
 - 3) $(\text{C}=\text{O})_a\text{O}_b\text{aryl}$,
 - 4) $\text{C}_2\text{-C}_{10}$ alkenyl,
 - 5) $\text{C}_2\text{-C}_{10}$ alkynyl,
 - 6) $(\text{C}=\text{O})_a\text{O}_b$ heterocyclyl,
 - 25 7) $(\text{C}=\text{O})_a\text{O}_b\text{C}_3\text{-C}_8$ cycloalkyl,
 - 8) CO_2H ,
 - 9) halo,
 - 10) CN,
 - 11) OH,
 - 30 12) $\text{O}_b\text{C}_1\text{-C}_6$ perfluoroalkyl,
 - 13) $\text{O}_a(\text{C}=\text{O})_b\text{NR}^6\text{R}^7$,
 - 14) $\text{NR}^c(\text{C}=\text{O})\text{NR}^6\text{R}^7$,
 - 15) $\text{S}(\text{O})_m\text{R}^a$,
 - 16) $\text{S}(\text{O})_2\text{NR}^6\text{R}^7$,

- 17) $\text{NR}^c\text{S}(\text{O})_m\text{R}^a$,
 18) oxo,
 19) CHO,
 20) NO_2 ,
 5 21) $\text{O}(\text{C}=\text{O})\text{O}_b\text{C}_1\text{-C}_{10}$ alkyl,
 22) $\text{O}(\text{C}=\text{O})\text{O}_b\text{C}_3\text{-C}_8$ cycloalkyl, and
 23) $\text{O}_a\text{-P}=\text{O}(\text{OH})_2$.

said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one or more substituents selected from R^Z ;

10

R^6 and R^7 are independently selected from:

- 1) H,
 2) $(\text{C}=\text{O})\text{O}_b\text{R}^a$,
 3) $\text{C}_1\text{-C}_{10}$ alkyl,
 15 4) aryl,
 5) $\text{C}_2\text{-C}_{10}$ alkenyl,
 6) $\text{C}_2\text{-C}_{10}$ alkynyl,
 7) heterocyclyl,
 8) $\text{C}_3\text{-C}_8$ cycloalkyl,
 20 9) SO_2R^a ,
 10) $(\text{C}=\text{O})\text{NR}^b_2$,
 11) OH, and
 12) $\text{O}_a\text{-P}=\text{O}(\text{OH})_2$.

25 said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R^Z , or

R^6 and R^7 can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 4-7 members in each ring and optionally containing, in addition to the nitrogen, one or more additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one or more substituents selected from R^Z ;

30

R^Z is selected from:

- 1) $(\text{C}=\text{O})_r\text{O}_s(\text{C}_1\text{-C}_{10})\text{alkyl}$,

- 2) $O_r(C_1-C_3)$ perfluoroalkyl,
 3) (C_0-C_6) alkylene- $S(O)_mR^a$,
 4) oxo,
 5) OH,
 5 6) halo,
 7) CN,
 8) $(C=O)_rO_s(C_2-C_{10})$ alkenyl,
 9) $(C=O)_rO_s(C_2-C_{10})$ alkynyl,
 10 10) $(C=O)_rO_s(C_3-C_6)$ cycloalkyl,
 11) $(C=O)_rO_s(C_0-C_6)$ alkylene-aryl,
 12) $(C=O)_rO_s(C_0-C_6)$ alkylene-heterocyclyl,
 13) $(C=O)_rO_s(C_0-C_6)$ alkylene- $N(R^b)_2$,
 14) $C(O)R^a$,
 15) (C_0-C_6) alkylene- CO_2R^a ,
 15 16) $C(O)H$,
 17) (C_0-C_6) alkylene- CO_2H ,
 18) $C(O)N(R^b)_2$,
 19) $S(O)_mR^a$,
 20) $S(O)_2N(R^b)_2$,
 20 21) $NR^c(C=O)O_bR^a$,
 22) $O(C=O)O_bC_1-C_{10}$ alkyl,
 23) $O(C=O)O_bC_3-C_8$ cycloalkyl,
 24) $O(C=O)O_b$ aryl,
 25) $O(C=O)O_b$ -heterocycle, and
 25 26) $O_a-P=O(OH)_2$,

said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heterocyclyl is optionally substituted with up to three substituents selected from R^b , OH, (C_1-C_6) alkoxy, halogen, CO_2H , CN, $O(C=O)C_1-C_6$ alkyl, oxo, $N(R^b)_2$ and $O_a-P=O(OH)_2$;

- 30 R^a is: substituted or unsubstituted (C_1-C_6) alkyl, substituted or unsubstituted (C_2-C_6) alkenyl, substituted or unsubstituted (C_2-C_6) alkynyl, substituted or unsubstituted (C_3-C_6) cycloalkyl, substituted or unsubstituted aryl, (C_1-C_6) perfluoroalkyl, 2,2,2-trifluoroethyl, or substituted or unsubstituted heterocyclyl; and

R^b is: H, (C₁-C₆)alkyl, substituted or unsubstituted aryl, substituted or unsubstituted benzyl, substituted or unsubstituted heterocyclyl, (C₃-C₆)cycloalkyl, (C=O)OC₁-C₆ alkyl, (C=O)C₁-C₆ alkyl or S(O)₂R^a;

5 R^c is selected from:


- 1) H,
- 2) C₁-C₁₀ alkyl,
- 3) aryl,
- 4) C₂-C₁₀ alkenyl,
- 10 5) C₂-C₁₀ alkynyl,
- 6) heterocyclyl,
- 7) C₃-C₈ cycloalkyl, and
- 8) C₁-C₆ perfluoroalkyl,

15 said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R^Z, or

or a pharmaceutically acceptable salt or a stereoisomer thereof.

2. The compound according to Claim 1 of the Formula B:

20



wherein:

25 $W=Y$ is selected from CR¹=N, N=CR¹;

or a pharmaceutically acceptable salt or a stereoisomer thereof.

3. The compound according to Claim 2 wherein:


Q is selected from: $-NR^6R^7$, phenyl and heterocyclyl which are optionally substituted with one to three R^Z ;

R^a is: (C_1-C_6) alkyl, (C_3-C_6) cycloalkyl, aryl, or heterocyclyl; and

R^b is: H, (C_1-C_6) alkyl, aryl, heterocyclyl, (C_3-C_6) cycloalkyl, $(C=O)OC_1-C_6$ alkyl, $(C=O)C_1-C_6$ alkyl or $S(O)_2R^a$;

or a pharmaceutically acceptable salt or a stereoisomer thereof.

4. The compound according to Claim 3 of the Formula C:



wherein:

Q is heterocyclyl, said heterocyclyl optionally substituted with 1 to 3 R^Z ;

R^2 is independently selected from:

- 1) C_1-C_6 alkyl,
- 2) aryl,
- 3) heterocyclyl,
- 4) CO_2H ,
- 5) halo,
- 6) CN ,
- 7) OH ,

8) $S(O)_2NR^6R^7$, and

9) $O_a-P=O(OH)_2$,

said alkyl, aryl and heterocyclyl optionally substituted with one, two or three substituents selected from R^Z ;

5

or a pharmaceutically acceptable salt or a stereoisomer thereof.

5. A compound which is selected from:

10 1-(1-{4-[3-(1,3-oxazol-2-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;

1-{1-[4-(6-phenyl-3-pyrimidin-2-yl-1,2,4-triazin-5-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;

15

1-(1-{4-[3-(1H-imidazol-2-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;

20 1-(1-{4-[3-(1-methyl-1H-pyrazol-5-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;

1-(1-{4-[6-phenyl-3-(1H-pyrazol-5-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;

25 1-(1-{4-[6-phenyl-3-(1H-pyrazol-5-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;

1-(1-{4-[3-(1-methyl-1H-pyrazol-4-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;

30

1-(1-{4-[3-(1-methyl-1H-imidazol-2-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;

- 1-{ 1-[4-(6-phenyl-3-tetrahydrofuran-3-yl-1,2,4-triazin-5-yl)benzyl]piperidin-4-yl}-
1,3-dihydro-2H-benzimidazol-2-one;
- 1-{ 1-[4-(6-phenyl-3-tetrahydrofuran-2-yl-1,2,4-triazin-5-yl)benzyl]piperidin-4-yl}-
5 1,3-dihydro-2H-benzimidazol-2-one;
- 1-{ 1-[4-(6-phenyl-3-thien-2-yl-1,2,4-triazin-5-yl)benzyl]piperidin-4-yl}-1,3-dihydro-
2H-benzimidazol-2-one;
- 10 1-(1-{ 4-[3-(4-methylmorpholin-3-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-
yl)-1,3-dihydro-2H-benzimidazol-2-one;
- 1-(1-{ 4-[3-(1-acetylazetid-3-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-
1,3-dihydro-2H-benzimidazol-2-one;
- 15 1-{ 1-[4-(6-phenyl-3-pyridin-2-yl-1,2,4-triazin-5-yl)benzyl]piperidin-4-yl}-1,3-
dihydro-2H-benzimidazol-2-one;
- 1-{ 1-[4-(6-phenyl-3-pyridin-3-yl-1,2,4-triazin-5-yl)benzyl]piperidin-4-yl}-1,3-
20 dihydro-2H-benzimidazol-2-one;
- 1-{ 1-[4-(6-phenyl-3-pyridin-4-yl-1,2,4-triazin-5-yl)benzyl]piperidin-4-yl}-1,3-
dihydro-2H-benzimidazol-2-one;
- 25 1-(1-{ 4-[3-(morpholin-4-ylmethyl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-
yl)-1,3-dihydro-2H-benzimidazol-2-one;
- 1-(1-{ 4-[6-phenyl-3-(1,3-thiazol-2-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-
dihydro-2H-benzimidazol-2-one;
- 30 1-(1-{ 4-[6-phenyl-3-(1,3-thiazol-5-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-
dihydro-2H-benzimidazol-2-one;
- 1-(1-{ 4-[6-phenyl-3-(1H-1,2,3-triazol-5-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-
35 1,3-dihydro-2H-benzimidazol-2-one;

1-(1-{4-[6-phenyl-3-(1,3-thiazol-4-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;

5 1-(1-{4-[3-(1,1'-biphenyl-4-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;

1-{1-[4-(2-methyl-3-oxo-6-phenyl-2,3-dihydro-1,2,4-triazin-5-yl)benzyl]piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;

10

1-{1-[4-(2-methyl-3-oxo-5-phenyl-2,3-dihydro-1,2,4-triazin-6-yl)benzyl]piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one; and

15 1-(1-{4-[3-(methylthio)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;

or a pharmaceutically acceptable salt or a stereoisomer thereof.

6. The TFA salt of a compound according to Claim 1 which is:

20

1-(1-{4-[3-(1,3-oxazol-2-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;

25 1-{1-[4-(6-phenyl-3-pyrimidin-2-yl-1,2,4-triazin-5-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;

1-(1-{4-[3-(1H-imidazol-2-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;

30 1-(1-{4-[3-(1-methyl-1H-pyrazol-5-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;

1-(1-{4-[6-phenyl-3-(1H-pyrazol-5-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;

35

- 1-(1-{4-[6-phenyl-3-(1H-pyrazol-5-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;
- 5 1-(1-{4-[3-(1-methyl-1H-pyrazol-4-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;
- 1-(1-{4-[3-(1-methyl-1H-imidazol-2-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;
- 10 1-{1-[4-(6-phenyl-3-tetrahydrofuran-3-yl-1,2,4-triazin-5-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;
- 1-{1-[4-(6-phenyl-3-tetrahydrofuran-2-yl-1,2,4-triazin-5-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;
- 15 1-{1-[4-(6-phenyl-3-thien-2-yl-1,2,4-triazin-5-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;
- 1-(1-{4-[3-(4-methylmorpholin-3-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;
- 20 1-(1-{4-[3-(1-acetylazetid-3-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;
- 25 1-{1-[4-(6-phenyl-3-pyridin-2-yl-1,2,4-triazin-5-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;
- 1-{1-[4-(6-phenyl-3-pyridin-3-yl-1,2,4-triazin-5-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;
- 30 1-{1-[4-(6-phenyl-3-pyridin-4-yl-1,2,4-triazin-5-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;
- 1-(1-{4-[3-(morpholin-4-ylmethyl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;
- 35

1-(1-{4-[6-phenyl-3-(1,3-thiazol-2-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;

- 5 1-(1-{4-[6-phenyl-3-(1,3-thiazol-5-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;

1-(1-{4-[6-phenyl-3-(1H-1,2,3-triazol-5-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;

10

1-(1-{4-[6-phenyl-3-(1,3-thiazol-4-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;

1-(1-{4-[3-(1,1'-biphenyl-4-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;

15

1-{1-[4-(2-methyl-3-oxo-6-phenyl-2,3-dihydro-1,2,4-triazin-5-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;

- 20 1-{1-[4-(2-methyl-3-oxo-5-phenyl-2,3-dihydro-1,2,4-triazin-6-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; and

1-(1-{4-[3-(methylthio)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;

25

or a stereoisomer thereof.

7. A compound according to Claim 5 which is selected from:

- 30 1-{1-[4-(6-phenyl-3-pyrimidin-2-yl-1,2,4-triazin-5-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;

1-(1-{4-[6-phenyl-3-(1H-1,2,3-triazol-5-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;

35

1-(1-{4-[6-phenyl-3-(1,3-thiazol-4-yl)-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one; and

1-(1-{4-[3-(1,1'-biphenyl-4-yl)-6-phenyl-1,2,4-triazin-5-yl]benzyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;

or a pharmaceutically acceptable salt or a stereoisomer thereof.

8. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 1.

9. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 5.

10. A method of inhibiting one or more of the isoforms of Akt in a mammal which comprises administering to the mammal a therapeutically effective amount of a compound of Claim 1.

11. A method of inhibiting one or more of the isoforms of Akt in a mammal which comprises administering to the mammal a therapeutically effective amount of a compound of Claim 5.

12. A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 1.

13. A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 5.

14. A method for treating a non-malignant disease in which angiogenesis is implicated which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 1.

5 15. A method for treating a non-malignant disease in which angiogenesis is implicated which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 5.

10 16. A pharmaceutical composition made by combining the compound of Claim 1 and a pharmaceutically acceptable carrier.

15 17. A process for making a pharmaceutical composition comprising combining a compound of Claim 1 and a pharmaceutically acceptable carrier.

18. The composition of Claim 8 further comprising a second compound selected from:

- 1) an estrogen receptor modulator,
- 2) an androgen receptor modulator,
- 20 3) a retinoid receptor modulator,
- 4) a cytotoxic agent,
- 5) an antiproliferative agent,
- 6) a prenyl-protein transferase inhibitor,
- 7) an HMG-CoA reductase inhibitor,
- 25 8) an HIV protease inhibitor,
- 9) a reverse transcriptase inhibitor,
- 10) an angiogenesis inhibitor,
- 11) a PPAR- γ agonist,
- 12) a PPAR- δ agonist,
- 30 13) an inhibitor of cell proliferation and survival signaling, and
- 14) an agent that interferes with a cell cycle checkpoint.

19. The composition of Claim 18, wherein the second compound is an angiogenesis inhibitor selected from the group consisting of a tyrosine kinase inhibitor, an inhibitor of epidermal-derived growth factor, an inhibitor of fibroblast-

35

derived growth factor, an inhibitor of platelet derived growth factor, an MMP inhibitor, an integrin blocker, interferon- α , interleukin-12, pentosan polysulfate, a cyclooxygenase inhibitor, carboxyamidotriazole, combretastatin A-4, squalamine, 6-O-(chloroacetyl-carbonyl)-fumagillol, thalidomide, angiostatin and troponin-1.

5

20. The composition of Claim 18, wherein the second compound is an estrogen receptor modulator selected from tamoxifen and raloxifene.

21. A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with radiation therapy.

10

22. A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with a second compound selected from:

15

- 1) an estrogen receptor modulator,
- 2) an androgen receptor modulator,
- 3) a retinoid receptor modulator,
- 4) a cytotoxic/cytostatic agent,
- 20 5) an antiproliferative agent,
- 6) a prenyl-protein transferase inhibitor,
- 7) an HMG-CoA reductase inhibitor,
- 8) an HIV protease inhibitor,
- 9) a reverse transcriptase inhibitor,
- 25 10) an angiogenesis inhibitor,
- 11) PPAR- γ agonists,
- 12) PPAR- δ agonists,
- 13) an inhibitor of inherent multidrug resistance,
- 14) an anti-emetic agent,
- 30 15) an agent useful in the treatment of anemia,
- 16) an agent useful in the treatment of neutropenia,
- 17) an immunologic-enhancing drug,
- 18) an inhibitor of cell proliferation and survival signaling, and
- 19) an agent that interferes with a cell cycle checkpoint.

35

23. A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with radiation therapy and a second compound selected from:

- 1) an estrogen receptor modulator,
- 2) an androgen receptor modulator,
- 3) a retinoid receptor modulator,
- 4) a cytotoxic/cytostatic agent,
- 5) an antiproliferative agent,
- 6) a prenyl-protein transferase inhibitor,
- 7) an HMG-CoA reductase inhibitor,
- 8) an HIV protease inhibitor,
- 9) a reverse transcriptase inhibitor,
- 10) an angiogenesis inhibitor,
- 11) PPAR- γ agonists,
- 12) PPAR- δ agonists,
- 13) an inhibitor of inherent multidrug resistance,
- 14) an anti-emetic agent,
- 15) an agent useful in the treatment of anemia,
- 16) an agent useful in the treatment of neutropenia,
- 17) an immunologic-enhancing drug,
- 18) an inhibitor of cell proliferation and survival signaling, and
- 19) an agent that interferes with a cell cycle checkpoint.

24. A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 and paclitaxel or trastuzumab.

25. A method of treating hyperproliferative disorders selected from restenosis, inflammation, autoimmune diseases and allergy/asthma which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 1.

26. A method of treating hyperinsulinism which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 1.

TITLE OF THE INVENTION
INHIBITORS OF AKT ACTIVITY

ABSTRACT OF THE DISCLOSURE

5 The present invention is directed to compounds which contain a
heterocyclic triazine moiety which inhibit the activity of Akt, a serine/threonine
protein kinase. The invention is further directed to chemotherapeutic compositions
containing the compounds of this invention and methods for treating cancer
comprising administration of the compounds of the invention.

10